(dp1
S'10.1016/j.ijid.2006.09.010'
p2
(lp3
S'nasal vaccine candidate'
p4
aS'nasal vaccine'
p5
aS'healthy adults'
p6
aS'adverse events were'
p7
aS'7 15 30'
p8
aS'30 and 60'
p9
aS'0 7 15'
p10
aS'Adverse events were'
p11
aS'nasal'
p12
aS'trial'
p13
aS'HBsAg and HBcAg'
p14
aS'hepatitis B virus'
p15
aS'data collection sheets'
p16
aS'placebo group'
p17
aS'anti HBc antibodies'
p18
aS'30 days after'
p19
aS'anti HBs antibody'
p20
asS'd'
(lp21
S'nasal vaccine candidate'
p22
aS'nasal vaccine'
p23
aS'healthy adults'
p24
aS'adverse events were'
p25
aS'7 15 30'
p26
aS'30 and 60'
p27
aS'0 7 15'
p28
aS'Adverse events were'
p29
aS'nasal'
p30
aS'trial'
p31
aS'HBsAg and HBcAg'
p32
aS'hepatitis B virus'
p33
aS'data collection sheets'
p34
aS'placebo group'
p35
aS'anti HBc antibodies'
p36
aS'30 days after'
p37
aS'anti HBs antibody'
p38
aS'50 g HBcAg'
p39
aS'50 g HBsAg'
p40
aS'Source data collection'
p41
aS'healthy'
p42
aS'day 30'
p43
aS'trial in healthy'
p44
aS'core antigens'
p45
aS'seroconversion in 100'
p46
aS'proportion of subjects'
p47
aS'vaccine'
p48
aS'HBsAg HBcAg vaccine'
p49
aS'HBcAg vaccine candidate'
p50
aS'60 days'
p51
aS'day 90 75'
p52
aS'HBs and anti'
p53
aS'9 8 palate'
p54
aS'9 8 headache'
p55
aS'34 1 rhinorrhea'
p56
aS'included sneezing 34'
p57
aS'8 palate itching'
p58
aS'2 nasal stuffiness'
p59
aS'12 2 nasal'
p60
aS'1 rhinorrhea 12'
p61
aS'mild in intensity'
p62
aS'events were recorded'
p63
aS'were recorded during'
p64
aS'anti HBc'
p65
aS'study'
p66
aS'anti HBc seroconversion'
p67
aS'well tolerated'
p68
aS'nasal route'
p69
aS'12h 24h 48h'
p70
aS'24h 48h 72h'
p71
aS'6h 12h 24h'
p72
aS'events were actively'
p73
aS'were actively recorded'
p74
aS'via nasal spray'
p75
aS'hepatitis B vaccine'
p76
aS'19 healthy male'
p77
aS'were randomly allocated'
p78
aS'systemic adverse events'
p79
aS'healthy male adults'
p80
aS'physiologic saline solution'
p81
aS'day 90'
p82
aS'CIGB Havana Cuba'
p83
aS'nasal co administration'
p84
aS'immunization schedule'
p85
aS'placebo'
p86
aS'HBs antibody levels'
p87
aS'Source data'
p88
aS'first'
p89
aS'B virus HBV'
p90
aS'safety and immunogenicity'
p91
aS'events were defined'
p92
aS'local adverse events'
p93
aS'events were reported'
p94
aS'clinical trial'
p95
aS'50'
p96
aS'responders anti HBs'
p97
aS'total'
p98
aS'day'
p99
aS'HBsAg HBcAg'
p100
aS'hepatitis B vaccines'
p101
aS'Center for Genetic'
p102
aS'Genetic Engineering Biotechnology'
p103
aS'strong immunogenicity'
p104
aS'clinical'
p105
aS'HBcAg and HBsAg'
p106
aS'45 years'
p107
aS'immunogenicity of HBcAg'
p108
aS'HBcAg'
p109
aS'route with 50'
p110
aS'g HBsAg following'
p111
aS'linked to 50'
p112
aS'HBcAg HBsAg vaccine'
p113
aS'response to HBcAg'
p114
aS'HBsAg vaccine candidate'
p115
aS'HBcAg non covalently'
p116
aS'candidate in healthy'
p117
aS'healthy volunteers immunized'
p118
aS'phase'
p119
aS'Center for Toxicology'
p120
aS'J Finlay Hospital'
p121
aS'Carlos J Finlay'
p122
aS'doses per study'
p123
aS'Frequency of each'
p124
aS'number of applied'
p125
aS'applied doses per'
p126
aS'per study group'
p127
aS'event with respect'
p128
aS'type of adverse'
p129
aS'well'
p130
aS'60'
p131
aS'severe'
p132
aS'vaccine candidate'
p133
aS'hepatitis'
p134
aS'vaccine recipients'
p135
aS'chronic'
p136
aS'nasal wash'
p137
aS'0 5ml'
p138
aS'chronic HBV infected'
p139
aS'19 healthy'
p140
aS'any'
p141
aS'World Health Organization'
p142
aS'results'
p143
aS'nasal co'
p144
aS'HBsAg'
p145
aS'subjects'
p146
aS'systemic adverse'
p147
aS'any other'
p148
aS'written informed consent'
p149
aS'immunization'
p150
aS'mice'
p151
aS'chronic infection'
p152
aS'adverse event'
p153
aS'other'
p154
aS'two'
p155
aS'vaccine group'
p156
aS'anti HBs'
p157
aS'Genetic Engineering'
p158
aS'chronic HBV'
p159
aS'volunteers'
p160
aS'immunogenic'
p161
aS'mixture of 50'
p162
aS'axillary temperature'
p163
aS'core'
p164
aS'immunity'
p165
aS'more than'
p166
aS'general malaise'
p167
aS'30 days'
p168
aS'systemic'
p169
aS'100'
p170
aS'systemic immunity'
p171
aS'anti'
p172
aS'each'
p173
aS'local adverse'
p174
aS'animal'
p175
aS'full length'
p176
aS'knowledge'
p177
aS'anti HBs titers'
p178
aS'events were mild'
p179
aS'safe'
p180
aS'applied doses'
p181
aS'placebo group withdrew'
p182
aS'study group'
p183
aS'virus'
p184
aS'patients with chronic'
p185
aS'intensity'
p186
aS'candidate comprising HBV'
p187
aS'study in healthy'
p188
aS'demonstration of safety'
p189
aS'safe well tolerated'
p190
aS'comprising HBV antigens'
p191
aS'tolerated and immunogenic'
p192
aS'vaccine candidate comprising'
p193
aS'unexpected events were'
p194
aS'using corresponding ELISA'
p195
aS'vaccine elicited anti'
p196
aS'tolerated Adverse reactions'
p197
aS'seroprotective anti HBs'
p198
aS'well tolerated Adverse'
p199
aS'dose Anti HBs'
p200
aS'elicited anti HBc'
p201
aS'each dose Anti'
p202
aS'after each dose'
p203
aS'titers were evaluated'
p204
aS'severe or unexpected'
p205
aS'reactions included sneezing'
p206
aS'per nostril Adverse'
p207
aS'early as day'
p208
aS'kits at days'
p209
aS'1h 6h 12h'
p210
aS'anti HBc titers'
p211
aS'recorded 1h 6h'
p212
aS'immunization schedule while'
p213
aS'100 of subjects'
p214
aS'were evaluated using'
p215
aS'nostril Adverse events'
p216
aS'actively recorded 1h'
p217
aS'evaluated using corresponding'
p218
aS'intensity No severe'
p219
aS'corresponding ELISA kits'
p220
aS'HBs titer 10IU'
p221
aS'days and 30'
p222
aS'days after each'
p223
aS'HBc titers were'
p224
aS'safe and well'
p225
aS'75 All subjects'
p226
aS'subjects as early'
p227
aS'placebo group remained'
p228
aS'30 and 90'
p229
aS'72h 7 days'
p230
aS'90 75 All'
p231
aS'8 and general'
p232
aS'group remained seronegative'
p233
aS'remained seronegative during'
p234
aS'maximum at day'
p235
aS'anti HBs titer'
p236
aS'limiting and mild'
p237
aS'reactions were all'
p238
aS'were all self'
p239
aS'all self limiting'
p240
aS'Adverse reactions included'
p241
aS'placebo via nasal'
p242
aS'five dose schedule'
p243
aS'administered in two'
p244
aS'0 9 physiologic'
p245
aS'9 physiologic saline'
p246
aS'NASVAC comprising hepatitis'
p247
aS'vaccine candidate NASVAC'
p248
aS'HBV surface HBsAg'
p249
aS'double blinded placebo'
p250
aS'profile of nasal'
p251
aS'safety and immunogenic'
p252
aS'candidate NASVAC comprising'
p253
aS'core antigens HBcAg'
p254
aS'HBV recombinant antigens'
p255
aS'administration of both'
p256
aS'randomized clinical trial'
p257
aS'markers of immunity'
p258
aS'both HBV recombinant'
p259
aS'according to Good'
p260
aS'guidelines Participants ranged'
p261
aS'immunogenic in animal'
p262
aS'HBsAg and core'
p263
aS'18 to 45'
p264
aS'infection to HBV'
p265
aS'aimed at exploring'
p266
aS'years and were'
p267
aS'allocated to receive'
p268
aS'Practice guidelines Participants'
p269
aS'Good Clinical Practice'
p270
aS'placebo controlled randomized'
p271
aS'ranged in age'
p272
aS'Clinical Practice guidelines'
p273
aS'blinded placebo controlled'
p274
aS'age from 18'
p275
aS'controlled randomized clinical'
p276
aS'virus HBV surface'
p277
aS'Source'
p278
aS'pre and post'
p279
aS'saliva and nasal'
p280
aS'nasal wash samples'
p281
aS'anterior and posterior'
p282
aS'covalently linked'
p283
aS'HBcAg HBsAg'
p284
aS'Antibody response'
p285
aS'healthy volunteers'
p286
aS'National Center'
p287
aS'Accuspray Becton Dickinson'
p288
aS'five'
p289
aS'full length HBcAg'
p290
aS'19'
p291
aS'each type'
p292
aS'total number'
p293
aS'concentration of anti'
p294
aS'reactions were'
p295
aS'more than 10IU'
p296
aS's exact test'
p297
aS'Fisher s exact'
p298
aS'also'
p299
aS'both'
p300
aS'early'
p301
aS'mean anti HBs'
p302
aS'confidence intervals were'
p303
aS'95 confidence intervals'
p304
aS'adverse events included'
p305
aS'linked immunosorbent assay'
p306
aS'enzyme linked immunosorbent'
p307
aS'C and any'
p308
aS'require medical attention'
p309
aS'may require medical'
p310
aS'combined to give'
p311
aS'age'
p312
aS'recombinant'
p313
aS'strong'
p314
aS'adverse events'
p315
aS'administered'
p316
aS'performed'
p317
aS'seroprotective'
p318
aS'respect'
p319
aS'administration'
p320
aS'studied'
p321
aS'mucosal'
p322
aS'unexpected'
p323
aS'patients'
p324
aS'saliva'
p325
aS'double blinded'
p326
aS'approximately'
p327
aS'were randomly'
p328
aS'adverse'
p329
aS'dose schedule'
p330
aS'World Health'
p331
aS'used'
p332
aS'time'
p333
aS'related'
p334
aS'HBV'
p335
aS'participants'
p336
aS'safety'
p337
aS'had'
p338
aS'45'
p339
aS'90'
p340
aS'local'
p341
aS'HBV antigens'
p342
aS'Phase'
p343
aS'most'
p344
aS'first inoculation'
p345
aS'nasal spray'
p346
aS'mixture'
p347
aS'more'
p348
aS'infected patients'
p349
aS'co'
p350
aS'immunogenicity'
p351
aS'populations'
p352
aS'control'
p353
aS'Genetic'
p354
aS'antiviral'
p355
aS'schedule'
p356
aS'addition'
p357
aS'nasal mucosa'
p358
aS'carried'
p359
aS'adults'
p360
aS'dose'
p361
aS'second'
p362
aS'immune'
p363
aS'post immunization'
p364
aS'access'
p365
aS'immune system'
p366
aS'second dose'
p367
aS'Center'
p368
aS'geometric mean'
p369
aS'further'
p370
aS'antigens'
p371
aS'Preclinical'
p372
aS'antibody responses'
p373
aS'relevant'
p374
aS'recorded during'
p375
aS'demonstrated'
p376
aS'vaccine formulation'
p377
aS'devices'
p378
aS'self'
p379
aS'general'
p380
aS'proportion'
p381
aS'serum'
p382
aS'T cell'
p383
aS'study prior'
p384
aS'all'
p385
aS'Figure'
p386
aS'antigen'
p387
aS'days'
p388
aS'full'
p389
aS'detection'
p390
aS'high'
p391
aS'subjects reporting'
p392
aS'18'
p393
aS'mild'
p394
aS'safe well'
p395
aS'first demonstration'
p396
aS'vaccine elicited'
p397
aS'seroprotective anti'
p398
aS'unexpected events'
p399
aS'days 30'
p400
aS'placebo via'
p401
aS'five dose'
p402
aS'two dosages'
p403
aS'total volume'
p404
aS'highly immunogenic'
p405
aS'serologic markers'
p406
aS'immunity infection'
p407
aS'animal models'
p408
aS'performed according'
p409
aS'immunogenic profile'
p410
aS'both HBV'
p411
aS'Good Clinical'
p412
aS'applied'
p413
aS'covalently'
p414
aS'Antibody'
p415
aS'National'
p416
aS'Toxicology'
p417
aS'Carlos'
p418
aS'Anti HBc'
p419
aS'experiments'
p420
aS'immunity against'
p421
aS'95'
p422
aS'Frequency'
p423
aS'participants inoculated'
p424
aS'purified'
p425
aS'were'
p426
aS'data collection'
p427
aS'other nasal'
p428
aS'study nurse'
p429
aS'order'
p430
aS'vaccine were'
p431
aS'shown'
p432
aS'95 confidence'
p433
aS'EM analysis'
p434
aS'development'
p435
aS'sensitivity'
p436
aS'carriers'
p437
aS'single'
p438
aS'responders'
p439
aS'infected'
p440
aS'commercial'
p441
aS'30'
p442
aS'formulation'
p443
aS'75'
p444
aS'Anti'
p445
aS'each dose'
p446
aS'protein'
p447
aS'screening'
p448
aS'reactions'
p449
aS'combined'
p450
aS'Havana'
p451
aS'15'
p452
aS'fourth'
p453
aS'Th1'
p454
aS'same'
p455
aS'7 days'
p456
aS'6h 12h'
p457
aS'undertaken'
p458
aS'axillary'
p459
aS'events'
p460
aS'third'
p461
aS'group'
p462
aS'antibody'
p463
aS'required'
p464
aS'negative'
p465
aS'6h'
p466
aS'need'
p467
aS'increase'
p468
aS'World'
p469
aS'infection'
p470
aS'licensed hepatitis'
p471
aS'double'
p472
aS'frequency'
p473
aS'72h'
p474
aS'headache'
p475
aS'recombinant HBcAg'
p476
aS'All'
p477
aS'sneezing'
p478
aS'achieved'
p479
aS'very'
p480
aS'all participants'
p481
aS'candidate'
p482
aS'one'
p483
aS'induced'
p484
aS'Cuba'
p485
aS'participants were'
p486
aS'reported'
p487
aS'spray'
p488
aS'evaluated'
p489
aS'hematology'
p490
aS'primary'
p491
aS'recorded'
p492
aS'potential'
p493
aS'positive'
p494
aS'elicited'
p495
aS'events were'
p496
aS'tolerated'
p497
aS'revealed'
p498
aS'samples'
p499
aS'licensed'
p500
aS'staff'
p501
aS'device'
p502
aS'data'
p503
aS'collection'
p504
aS'written informed'
p505
aS'recording'
p506
aS'use'
p507
aS'125'
p508
aS'EM'
p509
aS'analysis'
p510
aS'sera'
p511
aS'10IU'
p512
aS'baseline'
p513
aS'successive'
p514
aS'route'
p515
aS'HBc'
p516
aS'HBs'
p517
aS'titers'
p518
aS'developed'
p519
aS'blinded'
p520
aS'blood'
p521
aS'seroprotection'
p522
aS'after'
p523
aS'profile'
p524
aS'days after'
p525
aS'15 30'
p526
aS'7 15'
p527
aS'seroconversion'
p528
aS'vaccines'
p529
aS'B vaccines'
p530
aS'according'
p531
aS'using'
p532
aS'against'
p533
aS'against HBV'
p534
aS'HBV infection'
p535
aS'hypo'
p536
aS'Engineering'
p537
aS'Engineering Biotechnology'
p538
aS'Biotechnology'
p539
aS'volunteer'
p540
aS'nasal adverse'
p541
aS'than'
p542
aS'type'
p543
aS'HBcAg vaccine'
p544
aS'response'
p545
aS'commercial anti'
p546
aS'subjects were'
p547
aS'10'
p548
aS'Adverse'
p549
aS'Adverse events'
p550
aS'rhinorrhea'
p551
aS'stuffiness'
p552
aS'nasal stuffiness'
p553
aS'itching'
p554
aS'palate itching'
p555
aS'palate'
p556
aS'considered'
p557
aS'studies'
p558
aS'abnormalities'
p559
aS'responses against'
p560
aS'responses'
p561
aS'clinically'
p562
aS'self limiting'
p563
aS'limiting'
p564
aS'obtained'
p565
aS'without'
p566
aS'treatment'
p567
aS'planned'
p568
aS'observation period'
p569
aS'doses'
p570
aS'titer'
p571
aS'remained'
p572
aS'group remained'
p573
aS'surface'
p574
aS'system'
p575
aS'present'
p576
aS'geometric'
p577
aS'90 75'
p578
aS'inoculation'
p579
aS'specific'
p580
aS'were mild'
p581
aS'per'
p582
aS'Havana Cuba'
p583
aS'post'
p584
aS'hyper responder'
p585
aS'basic'
p586
aS'g HBcAg'
p587
aS'g HBsAg'
p588
aS'12h'
p589
aS'Participants'
p590
aS'corresponding'
p591
aS'resulted'
p592
aS'event'
p593
aS'during'
p594
aS'seronegative'
p595
aS'standard'
p596
aS'enough'
p597
aS'included sneezing'
p598
aS'2 nasal'
p599
aS'sneezing 34'
p600
aS'12'
p601
aS'8 palate'
p602
aS'8 headache'
p603
aS'34'
p604
aS'1 rhinorrhea'
p605
aS'rhinorrhea 12'
p606
aS'included'
p607
aS'malaise'
p608
aS'remaining'
p609
aS'any local'
p610
aS'rates'
p611
aS'24h'
p612
aS'sample'
p613
aS'administered HBsAg'
p614
aS'activity'
p615
aS'human'
p616
aS'epistaxis'
p617
aS'were more'
p618
aS'HBV vaccine'
p619
aS'following'
p620
aS'sterile'
p621
aS'B virus'
p622
aS'randomized'
p623
aS'sera were'
p624
aS'recipients'
p625
aS'solution'
p626
aS'years'
p627
aS'were recorded'
p628
aS'maximum'
p629
aS'highly'
p630
aS'exploring'
p631
aS'Good'
p632
aS'aimed'
p633
aS'serologic'
p634
aS'receive'
p635
aS'collection sheets'
p636
aS'sheets'
p637
aS'between'
p638
aS'posterior'
p639
aS'cytotoxic'
p640
aS'fifth'
p641
aS'HBsAg following'
p642
aS'linked'
p643
aS'immunized'
p644
aS'HBsAg vaccine'
p645
aS'volunteers immunized'
p646
aS'Drug'
p647
aS'length'
p648
aS'size'
p649
aS'otorhinolaryngologist'
p650
aS'Finlay'
p651
aS'Finlay Hospital'
p652
aS'J Finlay'
p653
aS'Hospital'
p654
aS'confirmed'
p655
aS'adjuvant'
p656
aS'improved'
p657
aS'value'
p658
aS'novel'
p659
aS'drug'
p660
aS'responders anti'
p661
aS'per study'
p662
aS'number'
p663
aS'doses per'
p664
aS'concentration'
p665
aS'treatment group'
p666
aS'Fisher'
p667
aS'enhancement'
p668
aS'written'
p669
aS'based'
p670
aS'severity'
p671
aS'elicit'
p672
aS'work'
p673
aS'history'
p674
aS'potent'
p675
aS'showed'
p676
aS'Nasal administration'
p677
aS'chronic carriers'
p678
aS'HBc seroconversion'
p679
aS'intranasal'
p680
aS'address'
p681
aS'77'
p682
aS'Th cell'
p683
aS'nucleic acids'
p684
aS'previously'
p685
aS'enzyme linked'
p686
aS'expressed'
p687
aS'up'
p688
aS'CIGB'
p689
aS'study staff'
p690
aS'licensed nasal'
p691
aS'give'
p692
aS'formal'
p693
aS'fluorescent'
p694
aS'50g'
p695
aS'M cells'
p696
aS'against HBsAg'
p697
aS'fever'
p698
aS'under'
p699
aS'inflammatory'
p700
aS'significant'
p701
aS'resolving'
p702
aS'effects'
p703
aS'moderate'
p704
aS'received'
p705
aS'there'
p706
aS'over'
p707
aS'differences'
p708
aS'only'
p709
aS'were evaluated'
p710
aS'antibodies'
p711
aS'mucosa'
p712
aS'reporting'
p713
aS'significantly'
p714
aS'Anti HBs'
p715
aS'made'
p716
aS'damage'
p717
aS'ELISA'
p718
aS'ELISA kits'
p719
aS'kits'
p720
aS'observation'
p721
aS'assigned'
p722
aS'Furthermore'
p723
aS'HBV infected'
p724
aS'mean'
p725
aS'assessed'
p726
aS'within'
p727
aS'l per'
p728
aS'hyper'
p729
aS'higher'
p730
aS'serum antibody'
p731
aS'vaccine doses'
p732
aS'71'
p733
aS'mixed'
p734
aS'testing'
p735
aS'Nasal'
p736
aS'Health'
p737
aS'Organization'
p738
aS'Health Organization'
p739
aS'prior'
p740
aS'25'
p741
aS'12h 24h'
p742
aS'24h 48h'
p743
aS'48h 72h'
p744
aS'48h'
p745
aS'actively'
p746
aS'were actively'
p747
aS'actively recorded'
p748
aS'via nasal'
p749
aS'via'
p750
aS'after each'
p751
aS'vaccine dose'
p752
aS'wash'
p753
aS'pre'
p754
aS'defined'
p755
aS'conditions'
p756
aS'level'
p757
aS'NASVAC'
p758
aS'allocated'
p759
aS'saline solution'
p760
aS'saline'
p761
aS'volume'
p762
aS'5ml'
p763
aS'B vaccine'
p764
aS'per nostril'
p765
aS'nostril'
p766
aS'available'
p767
aS'showing'
p768
aS'controlled'
p769
aS'placebo controlled'
p770
aS'male'
p771
aS'healthy male'
p772
aS'methods'
p773
aS'randomly allocated'
p774
aS'randomly'
p775
aS'were also'
p776
aS'similar'
p777
aS'induction'
p778
aS'All subjects'
p779
aS'such'
p780
aS'provided'
p781
aS'component'
p782
aS'frequent'
p783
aS'cases'
p784
aS'measured'
p785
aS'medical'
p786
aS'than 10IU'
p787
aS'DC'
p788
aS'male adults'
p789
aS'test'
p790
aS'Individuals'
p791
aS'clearly'
p792
aS'containing'
p793
aS'Briefly'
p794
aS'thank'
p795
aS'seroprotected'
p796
aS'incubated'
p797
aS'physiologic'
p798
aS'physiologic saline'
p799
aS'comparison'
p800
aS'consent'
p801
aS'informed consent'
p802
aS'informed'
p803
aS'particle'
p804
aS'Recent'
p805
aS'tests'
p806
aS'proportional'
p807
aS'conjugate'
p808
aS'HBc antibodies'
p809
aS'purity'
p810
aS'estimated'
p811
aS'Similarly'
p812
aS'cells'
p813
aS'rats'
p814
aS'Th'
p815
aS'interaction'
p816
aS'nucleic'
p817
aS'neither'
p818
aS'enzyme'
p819
aS'Blood'
p820
aS'CIGB Havana'
p821
aS'particulate'
p822
aS'permanent'
p823
aS'bothersome'
p824
aS'subject'
p825
aS'Recombinant'
p826
aS'levels'
p827
aS'HB'
p828
aS'Heberbiovac HB'
p829
aS'Heberbiovac'
p830
aS'co administration'
p831
aS'hour'
p832
aS'hour after'
p833
aS'between vaccine'
p834
aS'period'
p835
aS'rate'
p836
aS'HBs antibody'
p837
aS'antibody levels'
p838
aS'subtype'
p839
aS'HBsAg subtype'
p840
aS'comprising'
p841
aS'Local'
p842
aS'against HBcAg'
p843
aS'Local site'
p844
aS'site'
p845
aS'through'
p846
aS'100IU'
p847
aS'acute'
p848
aS'Only'
p849
aS'intervals'
p850
aS'There'
p851
aS'There were'
p852
aS'virus HBV'
p853
aS'individuals'
p854
aS'withdrew'
p855
aS'nor'
p856
aS'responder'
p857
aS'adverse reactions'
p858
aS'symptom'
p859
aS'were defined'
p860
aS'nasal flu'
p861
aS'flu'
p862
aS'HBs titers'
p863
aS'were reported'
p864
aS'gene'
p865
aS'temperature'
p866
aS'cell'
p867
aS'following inoculation'
p868
aS'derived'
p869
aS'group withdrew'
p870
aS'inoculated'
p871
aS'needed'
p872
aS'reaction'
p873
aS'comprising HBV'
p874
aS'candidate comprising'
p875
aS'demonstration'
p876
aS'nostril Adverse'
p877
aS'75 All'
p878
aS'Adverse reactions'
p879
aS'titer 10IU'
p880
aS'titers were'
p881
aS'dose Anti'
p882
aS'recorded 1h'
p883
aS'seronegative during'
p884
aS'were all'
p885
aS'remained seronegative'
p886
aS'1h 6h'
p887
aS'evaluated using'
p888
aS'1h'
p889
aS'using corresponding'
p890
aS'HBc titers'
p891
aS'corresponding ELISA'
p892
aS'schedule while'
p893
aS'while'
p894
aS'elicited anti'
p895
aS'tolerated Adverse'
p896
aS'all self'
p897
aS'HBs titer'
p898
aS'reactions included'
p899
aS'dosages'
p900
aS'9 physiologic'
p901
aS'surface HBsAg'
p902
aS'guidelines'
p903
aS'comprising hepatitis'
p904
aS'blinded placebo'
p905
aS'recombinant antigens'
p906
aS'Practice guidelines'
p907
aS'antigens HBcAg'
p908
aS'controlled randomized'
p909
aS'randomized clinical'
p910
aS'models'
p911
aS'Participants ranged'
p912
aS'Clinical'
p913
aS'candidate NASVAC'
p914
aS'ranged'
p915
aS'Practice'
p916
aS'Clinical Practice'
p917
aS'guidelines Participants'
p918
aS'markers'
p919
aS'HBV recombinant'
p920
aS'HBV surface'
p921
aS'NASVAC comprising'
p922
aS'nature'
p923
aS'II'
p924
aS'protective'
p925
aS'wash samples'
p926
aS'protective levels'
p927
aS'dripping'
p928
aS'anterior'
p929
aS'samples were'
p930
aS'adjuvants'
p931
aS'Becton'
p932
aS'Accuspray Becton'
p933
aS'Dickinson'
p934
aS'Accuspray'
p935
aS'Becton Dickinson'
p936
aS'predominated'
p937
aS'conducted'
p938
aS'effect'
p939
aS'length HBcAg'
p940
aS'parenteral'
p941
aS'APCs'
p942
aS'collected'
p943
aS'UMELISA'
p944
aS'reported during'
p945
aS'assay'
p946
aS'nasally'
p947
aS'were given'
p948
aS'given'
p949
aS'HBc UMELISA'
p950
aS'products'
p951
aS's exact'
p952
aS'exact'
p953
aS'exact test'
p954
aS'immune response'
p955
aS'determinants'
p956
aS'nurse'
p957
aS'substrate'
p958
aS'phosphatase'
p959
aS'alkaline'
p960
aS'alkaline phosphatase'
p961
aS'symptoms'
p962
aS'doses were'
p963
aS'mean anti'
p964
aS'irritating'
p965
aS'known'
p966
aS'confidence'
p967
aS'confidence intervals'
p968
aS'intervals were'
p969
aS'Individuals were'
p970
aS'acids'
p971
aS'events included'
p972
aS'Solicited'
p973
aS'immunosorbent'
p974
aS'linked immunosorbent'
p975
aS'immunosorbent assay'
p976
aS'symptom graded'
p977
aS'graded'
p978
aS'interference'
p979
aS'frequently'
p980
aS'more frequently'
p981
aS'medical attention'
p982
aS'require medical'
p983
aS'may'
p984
aS'require'
p985
aS'attention'
p986
aS'may require'
p987
aS'reaction category'
p988
aS'category'
p989
aS'state'
p990
aS'sample size'
p991
aS'dosages of 125l'
p992
aS'Th1 response vital'
p993
aS'cost'
p994
aS'vital'
p995
aS'protein in suppressing'
p996
aS'125l per'
p997
aS'response vital'
p998
aS'suppressing'
p999
aS'125l'
p1000
aS'development of more'
p1001
aS'limited'
p1002
aS'candidate for nasal'
p1003
aS'Solicited systemic adverse'
p1004
aS'HBcAg over nasally'
p1005
aS'seroprotection rate'
p1006
aS'facilities'
p1007
aS'randomized placebo'
p1008
aS'hematology tests'
p1009
aS'annoying may require'
p1010
aS'appetite'
p1011
aS'appetite nausea vomiting'
p1012
aS'years There'
p1013
aS'five vaccine'
p1014
aS'group Sneezing'
p1015
aS'spray calcitonin'
p1016
aS'disability'
p1017
aS'height between'
p1018
aS'two participants'
p1019
aS'usual activity'
p1020
aS'Additionally'
p1021
aS'recording of local'
p1022
aS'within 72hours'
p1023
aS'collected at baseline'
p1024
aS'risk'
p1025
aS'physician'
p1026
aS'terminal'
p1027
aS'dripping nasal stuffiness'
p1028
aS'induce strong HBV'
p1029
aS'measured in saliva'
p1030
aS'ulceration and nasal'
p1031
aS'viral'
p1032
aS'immunization interval'
p1033
aS'antibody titer'
p1034
aS'frequent adverse'
p1035
aS'spray at days'
p1036
aS'high mucosal'
p1037
aS'observations at 6h'
p1038
aS'trial corresponding'
p1039
aS'estimates'
p1040
aS'children became'
p1041
aS'Quality Control CECMED'
p1042
aS'subjects having'
p1043
aS'study indicate'
p1044
aS'even'
p1045
aS'post inoculation'
p1046
aS'More than 97'
p1047
aS'HBcAg to act'
p1048
aS'abnormal baseline biochemistry'
p1049
aS'two moderate adverse'
p1050
aS'study screening'
p1051
aS'18 45 years'
p1052
aS'healthy young adults'
p1053
aS'chemical and basic'
p1054
aS'IgA'
p1055
aS'included fever'
p1056
aS'center randomized'
p1057
aS'antibodies were'
p1058
aS'behavioural changes'
p1059
aS'use Nasal'
p1060
aS'frequency of sneezing'
p1061
aS'more immunogenic'
p1062
aS'approximately 5 10'
p1063
aS'analysis Further'
p1064
aS'cutaneous rash Information'
p1065
aS'protection'
p1066
aS'enough to elicit'
p1067
aS'active'
p1068
aS'human sera Briefly'
p1069
aS'behavioral risk'
p1070
aS'formulation consisting'
p1071
aS'irritating potential acute'
p1072
aS'reports'
p1073
aS'Hospital Havana Cuba'
p1074
aS'taking into consideration'
p1075
aS'were kept under'
p1076
aS'Sera with undetectable'
p1077
aS'Recombinant HBsAg reacts'
p1078
aS'changes'
p1079
aS'antibody levels were'
p1080
aS'antibody were'
p1081
aS'explained'
p1082
aS'recipients at day'
p1083
aS'levels and 95'
p1084
aS'significantly higher'
p1085
aS'study vaccines'
p1086
aS'CTL'
p1087
aS'Individuals were excluded'
p1088
aS'moderate or severe'
p1089
aS'other nasal vaccines'
p1090
aS'specific helper'
p1091
aS'nasal itching palate'
p1092
aS'hospital'
p1093
aS'used in specific'
p1094
aS'sampling including antigen'
p1095
aS'tabulated'
p1096
aS'formulation Sterile physiologic'
p1097
aS'nasally administered drugs'
p1098
aS'125 l per'
p1099
aS'therefore'
p1100
aS'Preclinical studies'
p1101
aS'against HBV nucleocapsid'
p1102
aS'aware'
p1103
aS'98'
p1104
aS'muscle aches decreased'
p1105
aS'populations DC'
p1106
aS'Blood saliva'
p1107
aS'most commonly reported'
p1108
aS'administration also allows'
p1109
aS'97'
p1110
aS'All sera'
p1111
aS'HBeAg'
p1112
aS'race predominated'
p1113
aS'adverse event profile'
p1114
aS'anti HBV vaccine'
p1115
aS'mm'
p1116
aS'corresponding to headache'
p1117
aS'phase monoclonal'
p1118
aS'levels were expressed'
p1119
aS'seroconversion against HBcAg'
p1120
aS'6h and 12h'
p1121
aS'All aspects'
p1122
aS'9 Only'
p1123
aS'HBs titers around'
p1124
aS'indicated'
p1125
aS'HBc specific Th'
p1126
aS'were assigned'
p1127
aS'period following'
p1128
aS'persistently abnormal'
p1129
aS'commercial ultramicroanalytic'
p1130
aS'blood mononuclear cells'
p1131
aS'were classified'
p1132
aS'diseases immunosuppressive disorders'
p1133
aS'immunization Solicited'
p1134
aS'subtype CIGB Havana'
p1135
aS'competitive sequential immunoenzymatic'
p1136
aS'vital for viral'
p1137
aS'HBs anti HBc'
p1138
aS'acemannan'
p1139
aS'severe adverse'
p1140
aS'wash samples All'
p1141
aS'HBs antibody level'
p1142
aS'were monitored'
p1143
aS'block antigenic'
p1144
aS'high responders'
p1145
aS'22nm particle'
p1146
aS'dose of 50'
p1147
aS'polymerase'
p1148
aS'43 subjects signed'
p1149
aS'events were monitored'
p1150
aS'multiple comparisons Geometric'
p1151
aS'only 30 days'
p1152
aS'methods Concurrent comparison'
p1153
aS'Genbank accession number'
p1154
aS'device Accuspray'
p1155
aS'percentage anti'
p1156
aS'group with approximately'
p1157
aS'found in participants'
p1158
aS'were seronegative'
p1159
aS'usual activity frequent'
p1160
aS'seroconversion for anti'
p1161
aS'UMELISA Immunoassay'
p1162
aS'vaccine doses were'
p1163
aS'both antigens Rates'
p1164
aS'vaccines currently licensed'
p1165
aS'chronically'
p1166
aS'before'
p1167
aS'use Nasal spray'
p1168
aS'sequential'
p1169
aS'T lymphocytes CTL'
p1170
aS'randomized placebo controlled'
p1171
aS'production'
p1172
aS'nasal mucosa septum'
p1173
aS'Health Organization standard'
p1174
aS'400'
p1175
aS'methodologies for mucosal'
p1176
aS'contained 0 6ml'
p1177
aS'overcome'
p1178
aS'lymphocytes CTL level'
p1179
aS'antigenic determinants'
p1180
aS'other symptom'
p1181
aS'diseases'
p1182
aS'minimum ensured'
p1183
aS'immunoenzymatic'
p1184
aS'sequential immunoenzymatic assay'
p1185
aS'break'
p1186
aS'inoculation under'
p1187
aS'first hour'
p1188
aS'plates'
p1189
aS'immunogen'
p1190
aS'commercial anti HBV'
p1191
aS'Control'
p1192
aS'achieve protective'
p1193
aS'entire core'
p1194
aS'reasonably'
p1195
aS'classified'
p1196
aS'77 recorded adverse'
p1197
aS'existing antibody against'
p1198
aS'conjugate anti HBs'
p1199
aS'under routine use'
p1200
aS'thin cytoplasm'
p1201
aS'nasal adverse reactions'
p1202
aS'commercial anti HBs'
p1203
aS'per well coated'
p1204
aS'side'
p1205
aS'clinically apparent'
p1206
aS'periodical examinations'
p1207
aS'vaccine group reported'
p1208
aS'surface M cell'
p1209
aS'toxicology or otorhinolaryngology'
p1210
aS'nostril were given'
p1211
aS'very distressing interference'
p1212
aS'glycosylated'
p1213
aS'bleeding Solicited'
p1214
aS'device Accuspray Becton'
p1215
aS'seroprotective response'
p1216
aS'substantially'
p1217
aS'preliminary'
p1218
aS'higher than 10IU'
p1219
aS'network'
p1220
aS'prophylactic vaccines'
p1221
aS'characteristic'
p1222
aS'reported more'
p1223
aS'high responders anti'
p1224
aS'medicine'
p1225
aS'Toxicology CENATOX'
p1226
aS'vaccine antigens'
p1227
aS'screening at day'
p1228
aS'route showing'
p1229
aS'anti HBs anti'
p1230
aS'Conversely patients resolving'
p1231
aS'site adverse'
p1232
aS'monoclonal antibodies'
p1233
aS'day period following'
p1234
aS'B infection'
p1235
aS'cirrhosis'
p1236
aS'Concurrent comparison'
p1237
aS'participants prior'
p1238
aS'toxicity and local'
p1239
aS'HBc seroconversion after'
p1240
aS'detecting'
p1241
aS'were made'
p1242
aS'Sneezing palate itching'
p1243
aS'chronic diseases immunosuppressive'
p1244
aS'showed seroconversion'
p1245
aS'study after obtaining'
p1246
aS'had clinically'
p1247
aS'hematological parameters'
p1248
aS'inoculation Adverse'
p1249
aS'long term consequences'
p1250
aS'CENATOX and Carlos'
p1251
aS'doses were needed'
p1252
aS'mucosa septum'
p1253
aS'were combined'
p1254
aS'persistently abnormal baseline'
p1255
aS'sensitivity Similarly further'
p1256
aS'resolving spontaneously'
p1257
aS'signs nor behavioural'
p1258
aS'computer generated list'
p1259
aS'HBc antibody'
p1260
aS'observations'
p1261
aS'addition to self'
p1262
aS'HBsAgHBcAg'
p1263
aS'percentage'
p1264
aS'recent'
p1265
aS'Anti HBc antibody'
p1266
aS'percentages were compared'
p1267
aS'72h following'
p1268
aS'potential acute toxicity'
p1269
aS'HBsAg and 50g'
p1270
aS'there were more'
p1271
aS'other investigators'
p1272
aS'abnormalities in blood'
p1273
aS'HBs 10'
p1274
aS'vaccine using'
p1275
aS'likely'
p1276
aS'incubated with natural'
p1277
aS'sampling including'
p1278
aS'were mostly reported'
p1279
aS'plasmid'
p1280
aS'antigen presenting cells'
p1281
aS'intervals were estimated'
p1282
aS'enables'
p1283
aS'inoculation of any'
p1284
aS'modulatory'
p1285
aS'clinical situation'
p1286
aS'fashion'
p1287
aS'group Individuals'
p1288
aS'levels against HBsAg'
p1289
aS'renal dialysis patients'
p1290
aS'clinical chemistries'
p1291
aS'adverse events reported'
p1292
aS'collected and categorized'
p1293
aS'populations DC Additionally'
p1294
aS'time intervals'
p1295
aS'same time'
p1296
aS'72h after inoculation'
p1297
aS'Center Havana'
p1298
aS'Briefly UMELISA plates'
p1299
aS'infection Conversely patients'
p1300
aS'Conversely patients'
p1301
aS'nasal formulation'
p1302
aS'access Furthermore'
p1303
aS'month after'
p1304
aS'consequences of chronic'
p1305
aS'subtype obtained'
p1306
aS'Nasal spray devices'
p1307
aS'continuous'
p1308
aS'estimate each rate'
p1309
aS'immunization schedule Following'
p1310
aS'any other symptom'
p1311
aS'well known nasally'
p1312
aS'mouth'
p1313
aS'Two applications per'
p1314
aS'Nine participants'
p1315
aS'immunogenicity profile Recent'
p1316
aS'remaining determinants'
p1317
aS'experiments in mice'
p1318
aS'young adults'
p1319
aS'nucleocapsid'
p1320
aS'age weight'
p1321
aS'potential therapeutic'
p1322
aS'principle'
p1323
aS'75 seroprotection'
p1324
aS'72hours following inoculation'
p1325
aS'order to optimize'
p1326
aS'came'
p1327
aS'per well'
p1328
aS'Nasal administration also'
p1329
aS'value 0 05'
p1330
aS'chills headache'
p1331
aS'studies in mice'
p1332
aS'activity frequent'
p1333
aS'measurement of serum'
p1334
aS'events between'
p1335
aS'effects underlines'
p1336
aS'existing antibody'
p1337
aS'intranasal vaccine'
p1338
aS'devices Accuspray'
p1339
aS'5ml Participants'
p1340
aS'90 days'
p1341
aS'range 18 45'
p1342
aS'placebo study'
p1343
aS'combined prophylactic vaccines'
p1344
aS'aches decreased'
p1345
aS'Volunteers were'
p1346
aS'Preclinical mouse studies'
p1347
aS'natural HBsAg'
p1348
aS'immune compromised hosts'
p1349
aS'rabbit anti HBc'
p1350
aS'nasal adverse events'
p1351
aS'three doses were'
p1352
aS'15 minutes apart'
p1353
aS'pocket'
p1354
aS'severity mild moderate'
p1355
aS'polymerase and envelope'
p1356
aS'antibodies were measured'
p1357
aS'report'
p1358
aS'50g HBcAg'
p1359
aS'devices still need'
p1360
aS'infrequent'
p1361
aS'were instructed'
p1362
aS'microscopy'
p1363
aS'consisting'
p1364
aS'through novel'
p1365
aS'mouth Two'
p1366
aS'local damage'
p1367
aS'adverse events predominated'
p1368
aS'study products were'
p1369
aS'Nine participants received'
p1370
aS'100 showed seroconversion'
p1371
aS'experiments conducted'
p1372
aS'treatment display'
p1373
aS'peripheral'
p1374
aS'core antigen'
p1375
aS'alterations'
p1376
aS'dendritic cell'
p1377
aS'patients with self'
p1378
aS'result'
p1379
aS'access very specialized'
p1380
aS'total of two'
p1381
aS'virus HBV worldwide'
p1382
aS'blood samples were'
p1383
aS'other particulate'
p1384
aS'immunization interval protocol'
p1385
aS'500DC'
p1386
aS'frequent and annoying'
p1387
aS'applications per nostril'
p1388
aS'weak HBV'
p1389
aS'05'
p1390
aS'IU l according'
p1391
aS'also likely'
p1392
aS'core antigen gene'
p1393
aS'completion'
p1394
aS'protected'
p1395
aS'older individuals'
p1396
aS'tolerance'
p1397
aS'Clinically significant events'
p1398
aS'HBcAg molecule'
p1399
aS'were closely'
p1400
aS'glycosylated form'
p1401
aS'terms'
p1402
aS'g derived'
p1403
aS'visualization'
p1404
aS'weak'
p1405
aS'patients resolving acute'
p1406
aS'combined prophylactic'
p1407
aS'per nostril were'
p1408
aS'combined HBsAg'
p1409
aS'local and systemic'
p1410
aS'sterile conditions'
p1411
aS'cells PBMCs'
p1412
aS'medication prior inoculation'
p1413
aS'decreased appetite'
p1414
aS'adults Local'
p1415
aS'tests against'
p1416
aS'commercial recombinant'
p1417
aS'up to 71'
p1418
aS'were not involved'
p1419
aS'nasal dripping nasal'
p1420
aS'basis but adverse'
p1421
aS'made for multiple'
p1422
aS'any symptom graded'
p1423
aS'activity on co'
p1424
aS'reach 75 seroprotection'
p1425
aS'reagents 10'
p1426
aS'flu or other'
p1427
aS'revealed by EM'
p1428
aS'well tolerated safe'
p1429
aS'virus after treatment'
p1430
aS'10IU l seroprotection'
p1431
aS'height'
p1432
aS'frequently reported among'
p1433
aS'Board'
p1434
aS'Samples'
p1435
aS'international units per'
p1436
aS'inflammatory analgesics'
p1437
aS'specific post'
p1438
aS'vessel status after'
p1439
aS'fluorigenic'
p1440
aS'vaccine formulation Sterile'
p1441
aS'basis'
p1442
aS'three'
p1443
aS'5 10'
p1444
aS'severe adverse event'
p1445
aS'acids bound'
p1446
aS'formulation and devices'
p1447
aS'same typical'
p1448
aS'type of cytokine'
p1449
aS'life'
p1450
aS'hospitalization'
p1451
aS'efficacy'
p1452
aS'drugs'
p1453
aS'participants were seronegative'
p1454
aS'adverse effects'
p1455
aS'nasal drug'
p1456
aS'hepatitis B infection'
p1457
aS'exception'
p1458
aS'acceptable local adverse'
p1459
aS'Recombinant HBsAg'
p1460
aS'seroprotection with respect'
p1461
aS'events predominated over'
p1462
aS'titers against'
p1463
aS'spontaneously'
p1464
aS'cause interference'
p1465
aS'other reactions'
p1466
aS'years of age'
p1467
aS'procedure'
p1468
aS'life threatening'
p1469
aS'HBcAg as vaccine'
p1470
aS'Sterile physiologic'
p1471
aS'e g acemannan'
p1472
aS'Among'
p1473
aS'subjects were classified'
p1474
aS'impact of HBcAg'
p1475
aS'characterize'
p1476
aS'category and all'
p1477
aS'kind of vaccine'
p1478
aS'vaccine candidate were'
p1479
aS'Nasal spray'
p1480
aS'mouse'
p1481
aS'l low responders'
p1482
aS'immunogenicity studies'
p1483
aS'reported more frequently'
p1484
aS'resolving acute hepatitis'
p1485
aS'cellular responses'
p1486
aS'reports came'
p1487
aS'HBs alkaline'
p1488
aS'also no clinically'
p1489
aS'adults between'
p1490
aS'response in mice'
p1491
aS'serum clinical chemistry'
p1492
aS'vaccine candidate showed'
p1493
aS'day 30 one'
p1494
aS'independent'
p1495
aS'Genbank accession'
p1496
aS'double blinded study'
p1497
aS'formal hypothesis'
p1498
aS'possible'
p1499
aS'60 days All'
p1500
aS'nucleocapsid polymerase'
p1501
aS'co administered'
p1502
aS'All study products'
p1503
aS'antibodies in human'
p1504
aS'Solicited adverse'
p1505
aS'compared'
p1506
aS'adults between 18'
p1507
aS'kept'
p1508
aS'scenario'
p1509
aS'l All'
p1510
aS'HBV worldwide'
p1511
aS'aqueous and transparent'
p1512
aS'contact'
p1513
aS'otorhinolaryngologist examination'
p1514
aS'were more than'
p1515
aS'phase monoclonal antibodies'
p1516
aS'efficacy of antiviral'
p1517
aS'diarrhea'
p1518
aS'days and 90'
p1519
aS'biochemistry or hematology'
p1520
aS'inversely'
p1521
aS'0 73'
p1522
aS'protocol'
p1523
aS'active immunotherapy'
p1524
aS'third vaccine'
p1525
aS'Serious'
p1526
aS'l according'
p1527
aS'same time intervals'
p1528
aS'l Although anti'
p1529
aS'HBs antibodies were'
p1530
aS'cell populations'
p1531
aS'Genbank'
p1532
aS'ability of HBcAg'
p1533
aS'10 l based'
p1534
aS'2 6 13'
p1535
aS'previous'
p1536
aS'professional antigen presenting'
p1537
aS'HBs 100IU'
p1538
aS'antigens NASVAC'
p1539
aS'impaired T cell'
p1540
aS'devices still'
p1541
aS'0 9 sterile'
p1542
aS'other licensed'
p1543
aS'transformed'
p1544
aS'access very'
p1545
aS'evidenced'
p1546
aS'any general'
p1547
aS'drug behavioral'
p1548
aS'8 general malaise'
p1549
aS'advances'
p1550
aS'Clinically significant'
p1551
aS'weight and height'
p1552
aS'neither clinical adverse'
p1553
aS'screening reasons'
p1554
aS'Induction of immunity'
p1555
aS'expiration through'
p1556
aS'C terminal'
p1557
aS'considered hyper responders'
p1558
aS'All study'
p1559
aS'borosilicate 2R'
p1560
aS'apart'
p1561
aS'volunteers were'
p1562
aS'59'
p1563
aS'dosages of 125'
p1564
aS'Also'
p1565
aS'were registered'
p1566
aS'comparability'
p1567
aS'informative'
p1568
aS'immunosuppressive'
p1569
aS'rats revealed'
p1570
aS'measured by commercial'
p1571
aS'titers against HBsAg'
p1572
aS'improved in terms'
p1573
aS'nasal administration'
p1574
aS'buffer without any'
p1575
aS'million carriers'
p1576
aS'responses in mice'
p1577
aS'had abnormalities'
p1578
aS'blood vessel status'
p1579
aS'antibodies No volunteers'
p1580
aS'fifth vaccine'
p1581
aS'single otorhinolaryngologist'
p1582
aS'HBsAg subtype obtained'
p1583
aS'were excluded'
p1584
aS'received either'
p1585
aS'2 whereas systemic'
p1586
aS'antigen gene under'
p1587
aS'Solicited systemic'
p1588
aS'HBsAg and antibody'
p1589
aS'comments'
p1590
aS'seroprotection percentage'
p1591
aS'acknowledge Enrique Iglesias'
p1592
aS'participants were randomized'
p1593
aS'reasons for screen'
p1594
aS'nasal vaccines'
p1595
aS'HBV nucleocapsid'
p1596
aS'recorded by study'
p1597
aS'race predominated during'
p1598
aS'responders to licensed'
p1599
aS'vaccines plant'
p1600
aS'seroprotection over'
p1601
aS'Further'
p1602
aS'highest frequency'
p1603
aS'healthy male adult'
p1604
aS's visits'
p1605
aS'study were similar'
p1606
aS'presence of nucleic'
p1607
aS'activator enabling'
p1608
aS'need for development'
p1609
aS'months'
p1610
aS'nasal dripping'
p1611
aS'system Adverse events'
p1612
aS'staff or volunteers'
p1613
aS'reported by other'
p1614
aS'anti HBs antibodies'
p1615
aS'common scenario'
p1616
aS'nine participants'
p1617
aS'All anti'
p1618
aS'administration comprising HBsAg'
p1619
aS'under sterile conditions'
p1620
aS'nor induced local'
p1621
aS'blood samples'
p1622
aS'dialysis patients'
p1623
aS'placebo study staff'
p1624
aS'received study drug'
p1625
aS'P rez'
p1626
aS'nasal HBsAg HBcAg'
p1627
aS'internal medicine'
p1628
aS'following administration'
p1629
aS'also allows'
p1630
aS'seroconversion against'
p1631
aS'drug behavioral risk'
p1632
aS'support'
p1633
aS'W3110'
p1634
aS'HBc specific'
p1635
aS'vaccines administered through'
p1636
aS'predominated during'
p1637
aS'subjects received'
p1638
aS'posterior nasal'
p1639
aS'ultramicroanalytic enzyme'
p1640
aS'HBsAg and 50'
p1641
aS'head'
p1642
aS'antibody levels against'
p1643
aS'form'
p1644
aS'particulate nature'
p1645
aS'developed NASVAC'
p1646
aS'failure'
p1647
aS'0038 All reactions'
p1648
aS'trained physician specializing'
p1649
aS'recorded adverse'
p1650
aS'true'
p1651
aS'intervals were used'
p1652
aS'absent'
p1653
aS'formal sample size'
p1654
aS'axillary temperature 38'
p1655
aS'antigen presenting'
p1656
aS'sterile saline'
p1657
aS'group reported'
p1658
aS'until'
p1659
aS'phosphate'
p1660
aS'required intervention'
p1661
aS'Serious adverse events'
p1662
aS'between vaccine formulation'
p1663
aS'medication'
p1664
aS'Depending'
p1665
aS'presenting cells'
p1666
aS'within 72h after'
p1667
aS'substantially different than'
p1668
aS'Organization there were'
p1669
aS'principle of neutralization'
p1670
aS'vaccine candidate containing'
p1671
aS'total anti'
p1672
aS'limiting resolving'
p1673
aS'HBV vaccine such'
p1674
aS'dual behavior'
p1675
aS'single center'
p1676
aS'cirrhosis liver failure'
p1677
aS'Only two'
p1678
aS'any clinical data'
p1679
aS'comparisons Geometric mean'
p1680
aS'HBc antibodies 17'
p1681
aS'septum and mucosal'
p1682
aS'multiple comparisons'
p1683
aS'adverse signs nor'
p1684
aS'immunogenic hepatitis'
p1685
aS'HBs alkaline phosphatase'
p1686
aS'medication prior'
p1687
aS'profile Recent'
p1688
aS'system Adverse'
p1689
aS'Similarly further'
p1690
aS'10IU l low'
p1691
aS'effect of systemic'
p1692
aS'disappeared within'
p1693
aS'events were more'
p1694
aS'vaccines administered'
p1695
aS'Health Organization there'
p1696
aS'toxicological'
p1697
aS'period following administration'
p1698
aS'inability to contact'
p1699
aS'self reporting'
p1700
aS'damage In addition'
p1701
aS'administration of HBV'
p1702
aS'fact'
p1703
aS'single nasal vaccine'
p1704
aS'basic hematology'
p1705
aS'patients include'
p1706
aS'adult'
p1707
aS'recombinant HBcAg Biokit'
p1708
aS'Anti HBc UMELISA'
p1709
aS'detecting at least'
p1710
aS'activated'
p1711
aS'volunteer received'
p1712
aS'after each immunization'
p1713
aS'cirrhosis liver'
p1714
aS'Information on any'
p1715
aS'HBV chronically infected'
p1716
aS'ELISA adapted'
p1717
aS'disorders'
p1718
aS'mechanisms for antigen'
p1719
aS'institution Five'
p1720
aS'seroprotection rate increased'
p1721
aS'spray calcitonin salmon'
p1722
aS'defined as axillary'
p1723
aS'adjuvants gene'
p1724
aS'Two applications'
p1725
aS'functioning may require'
p1726
aS'response to HBsAg'
p1727
aS'solution Although there'
p1728
aS'small volumes'
p1729
aS'similar surveillance'
p1730
aS'virus treatment'
p1731
aS'NASVAC or placebo'
p1732
aS'event rate exceeded'
p1733
aS'doses 85'
p1734
aS'units per'
p1735
aS'used Genbank'
p1736
aS'mean antibody titer'
p1737
aS'well documented state'
p1738
aS'Volunteers'
p1739
aS'anti HBc UMELISA'
p1740
aS'chronic infection Conversely'
p1741
aS'prophylactic'
p1742
aS'antibody against hepatitis'
p1743
aS'cell activator enabling'
p1744
aS'applications per'
p1745
aS'received study'
p1746
aS'derived recombinant'
p1747
aS'reported previously'
p1748
aS'antibodies from serum'
p1749
aS'single center randomized'
p1750
aS'0 No abnormalities'
p1751
aS'absent mild'
p1752
aS'luminal surface through'
p1753
aS'prevent'
p1754
aS'bleeding Solicited systemic'
p1755
aS'48hours'
p1756
aS'intranasal vaccine candidate'
p1757
aS'T cell responses'
p1758
aS'undertaken to determine'
p1759
aS'tests against HBsAg'
p1760
aS'demonstrated seroconversion'
p1761
aS'qualitative detection'
p1762
aS'solution All'
p1763
aS'rash Information'
p1764
aS'seroprotected subjects'
p1765
aS'phosphate buffer'
p1766
aS'blood products'
p1767
aS'nasal administration comprising'
p1768
aS'adult volunteers Written'
p1769
aS'assistance'
p1770
aS'under sterile'
p1771
aS'HBc quantification'
p1772
aS'variables Adverse events'
p1773
aS'very specialized'
p1774
aS'acute toxicity'
p1775
aS'vaccine Furthermore'
p1776
aS'boost'
p1777
aS'than 400 million'
p1778
aS'filled'
p1779
aS'liter IU'
p1780
aS'were administered'
p1781
aS'statistically'
p1782
aS'any adverse'
p1783
aS'HBcAg combined'
p1784
aS'ulceration'
p1785
aS'vaccine candidate developed'
p1786
aS'Havana Cuba All'
p1787
aS'mononuclear cells'
p1788
aS'Each vial'
p1789
aS'groups'
p1790
aS'HBs UMELISA'
p1791
aS'along'
p1792
aS'disappeared'
p1793
aS'HBsAg Recombinant HBsAg'
p1794
aS'immunization further benefit'
p1795
aS'informed consent Individuals'
p1796
aS'Research Ethics Board'
p1797
aS'novel adjuvants'
p1798
aS'significant events'
p1799
aS'development of mucosal'
p1800
aS'events included fever'
p1801
aS'reagents'
p1802
aS'differences between'
p1803
aS'recipients 0 0038'
p1804
aS'administered drugs'
p1805
aS'permanent impairment'
p1806
aS'B virus anti'
p1807
aS'sneezing nasal'
p1808
aS'were found'
p1809
aS'nor behavioural'
p1810
aS'bulbs'
p1811
aS'vaccine using similar'
p1812
aS'remaining determinants After'
p1813
aS'sterile phosphate'
p1814
aS'vaccines vaccines'
p1815
aS'lymphocytes CTL'
p1816
aS'visit'
p1817
aS'optimize'
p1818
aS'mucosal nasal'
p1819
aS'least one'
p1820
aS'scenario in patients'
p1821
aS'HBV core'
p1822
aS'hospital for 48hours'
p1823
aS'response in up'
p1824
aS'normal functioning'
p1825
aS'purified from strain'
p1826
aS'organized'
p1827
aS'acceptable'
p1828
aS'apparent'
p1829
aS'envelope'
p1830
aS'were undertaken'
p1831
aS'Recent developments'
p1832
aS'Subjects were healthy'
p1833
aS'participants as minimum'
p1834
aS'400 million'
p1835
aS'Binomial distribution point'
p1836
aS'recombinant Heberbiovac'
p1837
aS'list of random'
p1838
aS'hospitalizations were'
p1839
aS'borosilicate'
p1840
aS'were negative'
p1841
aS'polyclonal and multi'
p1842
aS'28nm as characterized'
p1843
aS'actively and always'
p1844
aS'cell pockets'
p1845
aS'labeled'
p1846
aS'obtained from serum'
p1847
aS'assay anti HBs'
p1848
aS'contact after'
p1849
aS'all other'
p1850
aS'septum'
p1851
aS'Each vial contained'
p1852
aS'g acemannan'
p1853
aS'were assigned arbitrarily'
p1854
aS'18 and 45'
p1855
aS'sera Briefly'
p1856
aS'T cell immunity'
p1857
aS'tilted backwards'
p1858
aS'detect differences'
p1859
aS'group withdrew voluntarily'
p1860
aS'allowed'
p1861
aS'72h after'
p1862
aS'Induction'
p1863
aS'containing recombinant'
p1864
aS'cells M cells'
p1865
aS'CECMED in Cuba'
p1866
aS'dialysis'
p1867
aS'remaining 19 participants'
p1868
aS'immunity Nasal administration'
p1869
aS'chemical'
p1870
aS'level in patients'
p1871
aS'criterion'
p1872
aS'stored in borosilicate'
p1873
aS'terms of sensitivity'
p1874
aS'further benefit'
p1875
aS'contribute'
p1876
aS'immunomodulation on HBsAg'
p1877
aS'spray device'
p1878
aS'strong mucosal'
p1879
aS'500DC mm'
p1880
aS'applications'
p1881
aS'graded as moderate'
p1882
aS'work efficiently'
p1883
aS'performed periodical'
p1884
aS'designed'
p1885
aS'reactions were self'
p1886
aS'placebo delivered'
p1887
aS'vaccine Heberbiovac HB'
p1888
aS'natural'
p1889
aS'liquid'
p1890
aS'persistent or permanent'
p1891
aS'tryptophan promoter'
p1892
aS'vaccine candidate tested'
p1893
aS'second vaccine doses'
p1894
aS'standard parenteral HBV'
p1895
aS'form HBcAg'
p1896
aS'were healthy male'
p1897
aS'immunogen even without'
p1898
aS'ultramicroanalytic'
p1899
aS'HBs equal'
p1900
aS'typical'
p1901
aS'site adverse events'
p1902
aS'72h following inoculation'
p1903
aS'expressed and purified'
p1904
aS'number X02763'
p1905
aS'appetite nausea'
p1906
aS'products were'
p1907
aS'400 million carriers'
p1908
aS'statistical'
p1909
aS'one adverse'
p1910
aS'still'
p1911
aS'microscopy EM'
p1912
aS'monitor'
p1913
aS'local tolerance All'
p1914
aS'proportion hypo'
p1915
aS'adverse event rate'
p1916
aS'B virus treatment'
p1917
aS'useful to overcome'
p1918
aS'HBV chronic infection'
p1919
aS'included persistently'
p1920
aS'nasal vaccine Furthermore'
p1921
aS'nose or digestive'
p1922
aS'uptake'
p1923
aS'serum antibody response'
p1924
aS'than 400'
p1925
aS'resulted in recent'
p1926
aS'phase antigen'
p1927
aS'protein expressed'
p1928
aS'titers around'
p1929
aS'obtaining'
p1930
aS'bound'
p1931
aS'congestion sneezing'
p1932
aS'were eligible'
p1933
aS'limited HBV'
p1934
aS'acknowledge Enrique'
p1935
aS'HBcAg particles'
p1936
aS'Dawley rats'
p1937
aS'HBcAg Biokit Barcelona'
p1938
aS'conjugate anti'
p1939
aS'term'
p1940
aS'UMELISA Immunoassay Center'
p1941
aS'immunoglobulin within'
p1942
aS'proteins'
p1943
aS'total of 43'
p1944
aS'vaccine only'
p1945
aS'85'
p1946
aS'control group'
p1947
aS'study screening reasons'
p1948
aS'following inoculation Adverse'
p1949
aS'abnormal'
p1950
aS'achieve protective anti'
p1951
aS'balanced'
p1952
aS'sponsor'
p1953
aS'year'
p1954
aS'recombinant HBsAg'
p1955
aS'anti HBc quantification'
p1956
aS'induced local'
p1957
aS'Solid phase'
p1958
aS'limited HBV infection'
p1959
aS'borosilicate 2R bulbs'
p1960
aS'continuous variables'
p1961
aS'doses were administered'
p1962
aS'sneezing nasal itching'
p1963
aS'responses against HBV'
p1964
aS'contained'
p1965
aS'according to otorhinolaryngologist'
p1966
aS'8IU'
p1967
aS'vaccine candidate administered'
p1968
aS'helpful comments'
p1969
aS'virus anti'
p1970
aS'format using'
p1971
aS'sense although three'
p1972
aS'excluded from enrollment'
p1973
aS'million'
p1974
aS'year 2000 Among'
p1975
aS'possibility'
p1976
aS'block antigenic determinants'
p1977
aS'secreted'
p1978
aS'first vaccine'
p1979
aS'reacting with remaining'
p1980
aS'generating more than'
p1981
aS'Enrique Iglesias'
p1982
aS'against both'
p1983
aS'virus control'
p1984
aS'allowed expiration through'
p1985
aS'Participants allocated'
p1986
aS'still need'
p1987
aS'also thank'
p1988
aS'routes'
p1989
aS'therapeutic use'
p1990
aS'itching palate itching'
p1991
aS'event in both'
p1992
aS'B cells'
p1993
aS'Sprague'
p1994
aS'symptoms very'
p1995
aS'variables'
p1996
aS'antibody were assigned'
p1997
aS'subjects showing'
p1998
aS'HBc alkaline phosphatase'
p1999
aS'defined as events'
p2000
aS'trial phase'
p2001
aS'Rates'
p2002
aS'periodical'
p2003
aS'comprises'
p2004
aS'100 showed'
p2005
aS'5 More than'
p2006
aS'one adverse event'
p2007
aS'transient nasal conditions'
p2008
aS'group included'
p2009
aS'vaccine or placebo'
p2010
aS'nasal itching'
p2011
aS'nasal spray calcitonin'
p2012
aS'impairment or damage'
p2013
aS'indicate'
p2014
aS'candidate containing recombinant'
p2015
aS'recognize any'
p2016
aS'white'
p2017
aS'cell populations DC'
p2018
aS'systemic immunity Nasal'
p2019
aS'Sneezing'
p2020
aS'mostly'
p2021
aS'II clinical studies'
p2022
aS'either NASVAC'
p2023
aS'immunomodulation'
p2024
aS'even without'
p2025
aS'study personnel before'
p2026
aS'alone or mixed'
p2027
aS'HBcAg CIGB'
p2028
aS'control Recombinant'
p2029
aS'clinical adverse signs'
p2030
aS'9 8 general'
p2031
aS'control Recombinant HBcAg'
p2032
aS'seroconversion after immunization'
p2033
aS'any study'
p2034
aS'13'
p2035
aS'effective'
p2036
aS'17'
p2037
aS'expressed as international'
p2038
aS'Five doses'
p2039
aS'institution Five doses'
p2040
aS'medical consultations'
p2041
aS'typical sandwich'
p2042
aS'within 72h'
p2043
aS'outcome'
p2044
aS'other symptom graded'
p2045
aS'addition of HBcAg'
p2046
aS'under observation'
p2047
aS'HBs or anti'
p2048
aS'other mucosal adjuvant'
p2049
aS'pre existing antibody'
p2050
aS'HBsAg reacts'
p2051
aS'rate percentages were'
p2052
aS'peptide vaccine'
p2053
aS'underlines'
p2054
aS'90 of children'
p2055
aS'up to 20'
p2056
aS'sensitivity Similarly'
p2057
aS'immunogen even'
p2058
aS'30 to get'
p2059
aS'instructed'
p2060
aS'19 participants'
p2061
aS'performance'
p2062
aS'impairment'
p2063
aS'l low'
p2064
aS'analysis Further antigenicity'
p2065
aS'HBV infected patients'
p2066
aS'multiple'
p2067
aS'trace'
p2068
aS'specific Th'
p2069
aS'Biotechnology in Havana'
p2070
aS'50g HBsAg'
p2071
aS'gene under'
p2072
aS'molecule'
p2073
aS'0 5ml Participants'
p2074
aS'study 100'
p2075
aS'positive or negative'
p2076
aS'detect'
p2077
aS'significantly increases'
p2078
aS'previous findings'
p2079
aS'Th1 type'
p2080
aS'characteristic of HBV'
p2081
aS'cellular responses against'
p2082
aS'adverse signs'
p2083
aS'participant s head'
p2084
aS'Becton Dickinson Depending'
p2085
aS'determinants After'
p2086
aS'renal'
p2087
aS'without any adjuvant'
p2088
aS'majority of infected'
p2089
aS'professional'
p2090
aS'were expressed'
p2091
aS'estimated by treatment'
p2092
aS'rate percentages'
p2093
aS'substantially different'
p2094
aS'virus as well'
p2095
aS'severity Binomial distribution'
p2096
aS'accession'
p2097
aS'parenteral administered HBsAg'
p2098
aS'tryptophan'
p2099
aS'HBsAg titer'
p2100
aS'events 58'
p2101
aS'ratio'
p2102
aS'All blood'
p2103
aS'male adult volunteers'
p2104
aS'study group included'
p2105
aS'potential acute'
p2106
aS'otorhinolaryngology'
p2107
aS'Concurrent'
p2108
aS'Binomial'
p2109
aS'Severe reactions were'
p2110
aS'HBs protective levels'
p2111
aS'previously for other'
p2112
aS'showed protective levels'
p2113
aS'More than'
p2114
aS'get'
p2115
aS'history of hepatitis'
p2116
aS'reported among'
p2117
aS'mixed with other'
p2118
aS'candidate demonstrated'
p2119
aS'ultramicroanalytic enzyme linked'
p2120
aS'S protein expressed'
p2121
aS'13 excess'
p2122
aS'secondary'
p2123
aS'same typical sandwich'
p2124
aS'regarding'
p2125
aS'vaccine Furthermore participants'
p2126
aS'age of participants'
p2127
aS'axillary temperature 39'
p2128
aS'symptom bothersome'
p2129
aS'physicians or volunteers'
p2130
aS'infection resolving'
p2131
aS'M cells transport'
p2132
aS'were used'
p2133
aS'true adverse event'
p2134
aS'audited'
p2135
aS'frequency of local'
p2136
aS'HBV core HBc'
p2137
aS'HBV nucleocapsid polymerase'
p2138
aS'adapted to small'
p2139
aS'sterile aqueous'
p2140
aS'cell immune response'
p2141
aS'per liter IU'
p2142
aS'2IU'
p2143
aS'licensed HBV'
p2144
aS'Hospital Havana'
p2145
aS'Organization standard'
p2146
aS'itching rhinorrhea nasal'
p2147
aS'investigators with licensed'
p2148
aS'study one subject'
p2149
aS'one month'
p2150
aS'blood screening regarding'
p2151
aS'candidate were'
p2152
aS'seronegative for anti'
p2153
aS'diarrhea and cutaneous'
p2154
aS'total of 77'
p2155
aS'mostly reported'
p2156
aS'1 hour'
p2157
aS'subjects were considered'
p2158
aS'similar surveillance methods'
p2159
aS'therapies'
p2160
aS'schedule Following administration'
p2161
aS'moderate adverse events'
p2162
aS'healthy adults Local'
p2163
aS'fluorescent signal'
p2164
aS'B vaccine candidate'
p2165
aS'personnel before'
p2166
aS'screen'
p2167
aS'g acemannan Whether'
p2168
aS'induced serum antibody'
p2169
aS'gratefully'
p2170
aS'chemistries and hematology'
p2171
aS'steroid'
p2172
aS'Each'
p2173
aS'also contribute'
p2174
aS'both reports came'
p2175
aS'HBsAg Recombinant'
p2176
aS'vaccine and one'
p2177
aS'purified recombinant'
p2178
aS'very specialized mechanisms'
p2179
aS'Sterile'
p2180
aS'vaccine were given'
p2181
aS'analgesics'
p2182
aS'residence'
p2183
aS'events did'
p2184
aS'more frequently reported'
p2185
aS'enabling'
p2186
aS'Chronic'
p2187
aS'participants were instructed'
p2188
aS'predominated over'
p2189
aS'induce strong'
p2190
aS'nor behavioural changes'
p2191
aS'vaccine recipients achieved'
p2192
aS'further studies'
p2193
aS'preclinical studies'
p2194
aS'Iglesias'
p2195
aS'immunity in chronic'
p2196
aS'were compared'
p2197
aS'77 adverse'
p2198
aS'studies were conducted'
p2199
aS'stored'
p2200
aS'them were'
p2201
aS'Recent advances'
p2202
aS'sampling'
p2203
aS'itching rhinorrhea'
p2204
aS'undetectable anti'
p2205
aS'most frequent adverse'
p2206
aS'considering'
p2207
aS'anosmia'
p2208
aS'achieved by nasal'
p2209
aS'Research'
p2210
aS'purified with recombinant'
p2211
aS'tonsils'
p2212
aS'registered Only'
p2213
aS'HBsAg and 100'
p2214
aS'antiviral immunogenicity'
p2215
aS'stuffiness and epistaxis'
p2216
aS'Clinically'
p2217
aS'immunopotentiating activity'
p2218
aS'sponsor institution'
p2219
aS'Subjects were'
p2220
aS'over systemic reactions'
p2221
aS'anti HBs 10'
p2222
aS'parenteral HBV'
p2223
aS'careful'
p2224
aS'73 provided'
p2225
aS'apparent abnormalities visualized'
p2226
aS'Biokit Barcelona Spain'
p2227
aS'plant derived vaccines'
p2228
aS'nasal flu vaccine'
p2229
aS'distressing'
p2230
aS'efficiently'
p2231
aS'T lymphocytes'
p2232
aS'buffer without'
p2233
aS'Spain'
p2234
aS'regarding chemical'
p2235
aS'vaccine doses Local'
p2236
aS'frequently in participants'
p2237
aS'region'
p2238
aS'clinically apparent abnormalities'
p2239
aS'used to estimate'
p2240
aS'HBc alkaline'
p2241
aS'within 72hours following'
p2242
aS'Iglesias P rez'
p2243
aS'compared by Fisher'
p2244
aS'them'
p2245
aS'equal'
p2246
aS'strain'
p2247
aS'good'
p2248
aS'inversely proportional'
p2249
aS'patients and carriers'
p2250
aS'were stored'
p2251
aS'long term'
p2252
aS'alterations or transient'
p2253
aS'diluted in sterile'
p2254
aS'helpful comments Finally'
p2255
aS'congestion sneezing nasal'
p2256
aS'encouraging taking'
p2257
aS'different'
p2258
aS'participant'
p2259
aS'through novel routes'
p2260
aS'spray device Accuspray'
p2261
aS'doctor'
p2262
aS'formulations'
p2263
aS'All but two'
p2264
aS'electron microscopy EM'
p2265
aS'surveillance'
p2266
aS'induction of immunity'
p2267
aS'further immunogenicity studies'
p2268
aS'full length recombinant'
p2269
aS'status'
p2270
aS'internal medicine toxicology'
p2271
aS'commonly reported'
p2272
aS'levels were'
p2273
aS'particulate antigens'
p2274
aS'0 0038 All'
p2275
aS'IU'
p2276
aS'formulation Phase II'
p2277
aS'Barcelona'
p2278
aS'route showing induction'
p2279
aS'sample size nine'
p2280
aS'l in order'
p2281
aS'seroprotected subjects were'
p2282
aS'total serum antibody'
p2283
aS'self limiting resolving'
p2284
aS'evaluated in duplicate'
p2285
aS'very encouraging'
p2286
aS'eligible'
p2287
aS'defined as absent'
p2288
aS'chronic patients include'
p2289
aS'became chronic carriers'
p2290
aS'steroid anti inflammatory'
p2291
aS'baseline 30'
p2292
aS'studies with HBsAg'
p2293
aS'other commercial'
p2294
aS'were more frequently'
p2295
aS'findings in experiments'
p2296
aS'cell immunity'
p2297
aS'inability'
p2298
aS'placebo group 59'
p2299
aS'g nasal flu'
p2300
aS'persistently'
p2301
aS'reporting adverse events'
p2302
aS'sprayed'
p2303
aS'Only anti HBs'
p2304
aS'levels against'
p2305
aS'among'
p2306
aS'adjustments'
p2307
aS'local or systemic'
p2308
aS'cytotoxic T cell'
p2309
aS'showed protective'
p2310
aS'Solicited adverse events'
p2311
aS'all participants were'
p2312
aS'behavioural'
p2313
aS'72hours following'
p2314
aS'comparisons Geometric'
p2315
aS'infrequent Adverse events'
p2316
aS'rats revealed neither'
p2317
aS'strong mucosal immunogenicity'
p2318
aS'patients include combined'
p2319
aS'placebo All study'
p2320
aS'immunogenicity of nasal'
p2321
aS'such samples'
p2322
aS'90 day period'
p2323
aS'Ethics'
p2324
aS'antigenicity studies'
p2325
aS'aspects'
p2326
aS'around'
p2327
aS'blinded fashion'
p2328
aS'mucosal alterations'
p2329
aS'were monitored over'
p2330
aS'recipient'
p2331
aS'90 applied doses'
p2332
aS'infected patient'
p2333
aS'were estimated pre'
p2334
aS'aqueous'
p2335
aS'irritating nor induced'
p2336
aS'corroborates previous'
p2337
aS'failures included'
p2338
aS'45 years There'
p2339
aS'envelope proteins'
p2340
aS'benefit'
p2341
aS'Subjects'
p2342
aS'either'
p2343
aS'hematology values'
p2344
aS'side effects'
p2345
aS'reported by 15'
p2346
aS'64'
p2347
aS'voluntarily'
p2348
aS'partial efficacy'
p2349
aS'recognize'
p2350
aS'candidate whereas systemic'
p2351
aS'50 g derived'
p2352
aS'than 97'
p2353
aS'than 95'
p2354
aS'influenza nasal flu'
p2355
aS'assay ELISA adapted'
p2356
aS'immunization with HBsAg'
p2357
aS'ability'
p2358
aS'HBcAg considering'
p2359
aS'HBsAg alone'
p2360
aS'doses Local'
p2361
aS'response to major'
p2362
aS'dependent and independent'
p2363
aS'specializing'
p2364
aS'allocation All'
p2365
aS'palate itching anosmia'
p2366
aS'cytotoxic T lymphocytes'
p2367
aS'chronic HBV infection'
p2368
aS'visits'
p2369
aS'7 years range'
p2370
aS'solid phase monoclonal'
p2371
aS'50 g purified'
p2372
aS'PBMCs from patients'
p2373
aS'nasal vaccine formulation'
p2374
aS'fifth dose'
p2375
aS'25 showed'
p2376
aS'categorized by body'
p2377
aS'cost and side'
p2378
aS'post immunization sera'
p2379
aS'apart All subjects'
p2380
aS'mice reconstituted'
p2381
aS'pockets'
p2382
aS'act'
p2383
aS'local tolerance'
p2384
aS'code labeled'
p2385
aS'Information'
p2386
aS'other mucosal'
p2387
aS'prolonged hospitalization'
p2388
aS'study and control'
p2389
aS'without any'
p2390
aS'major HBV'
p2391
aS'terminal region'
p2392
aS'trial were'
p2393
aS'HBsAg 10IU'
p2394
aS'immunogenicity Preclinical'
p2395
aS'determine'
p2396
aS'immunization further'
p2397
aS'intervention'
p2398
aS'proportion hypo responders'
p2399
aS'conflict of interest'
p2400
aS'g derived recombinant'
p2401
aS'g influenza nasal'
p2402
aS'than 95 purity'
p2403
aS'underwent pre study'
p2404
aS'enhancement observed'
p2405
aS'low'
p2406
aS'days All sera'
p2407
aS'secretion'
p2408
aS'needed to reach'
p2409
aS'30 Thirty'
p2410
aS'were self limiting'
p2411
aS'also allows interaction'
p2412
aS'professional antigen'
p2413
aS'Individuals were eligible'
p2414
aS'hyper responders'
p2415
aS'l One recipient'
p2416
aS'HBs anti'
p2417
aS'human clinical'
p2418
aS'physician specializing'
p2419
aS'antigenicity studies were'
p2420
aS'first report'
p2421
aS'combined formulations'
p2422
aS'Sprague Dawley'
p2423
aS'antigen gene'
p2424
aS'temperature 38'
p2425
aS'labeled matched pre'
p2426
aS'surface and core'
p2427
aS'side effects underlines'
p2428
aS'were conducted'
p2429
aS'dose however five'
p2430
aS'dose schedule formulation'
p2431
aS'inoculation Blood'
p2432
aS'wash samples were'
p2433
aS'interval'
p2434
aS'USA'
p2435
aS'l Sera'
p2436
aS'measurement'
p2437
aS'reporting adverse'
p2438
aS'blood mononuclear'
p2439
aS'enable'
p2440
aS'Th1 response'
p2441
aS'point estimates'
p2442
aS'size of 28nm'
p2443
aS'nasally administered'
p2444
aS'recombinant full'
p2445
aS'biochemistry'
p2446
aS'2000'
p2447
aS'underwent pre'
p2448
aS'efficiently as primary'
p2449
aS'comments Finally'
p2450
aS'pre incubated'
p2451
aS'More'
p2452
aS'presenting'
p2453
aS'requested'
p2454
aS'antibody titers'
p2455
aS'Preclinical toxicological studies'
p2456
aS'otorhinolaryngology Neither'
p2457
aS'more than 95'
p2458
aS'potent immunogen'
p2459
aS'post inoculation adverse'
p2460
aS'specializing in internal'
p2461
aS'each nostril'
p2462
aS'vaccine candidate demonstrated'
p2463
aS'irritating nor'
p2464
aS'any general reaction'
p2465
aS'documented state'
p2466
aS'liquid Each'
p2467
aS'event profile under'
p2468
aS'Briefly UMELISA'
p2469
aS'mixed with 50'
p2470
aS'were recruited'
p2471
aS'immunoglobulin'
p2472
aS'placebo All'
p2473
aS'behavioral'
p2474
aS'other developed'
p2475
aS'per liter'
p2476
aS'influenza'
p2477
aS'estimated pre'
p2478
aS'consider'
p2479
aS'more immunogenic hepatitis'
p2480
aS'caused'
p2481
aS'withdrew voluntarily'
p2482
aS'month'
p2483
aS'vaccines currently'
p2484
aS'25 showed protective'
p2485
aS'first and second'
p2486
aS'basic hematological'
p2487
aS'HBsAgHBcAg vaccine'
p2488
aS'tabulated by time'
p2489
aS'related to any'
p2490
aS'children'
p2491
aS'2R bulbs'
p2492
aS'monitored over'
p2493
aS'two seroprotected'
p2494
aS'frequent adverse events'
p2495
aS'entire core antigen'
p2496
aS'events predominated'
p2497
aS'novel adjuvants gene'
p2498
aS'cells APCs'
p2499
aS'HBcAg had'
p2500
aS'risk factors'
p2501
aS'M cell'
p2502
aS'liter'
p2503
aS'geometric mean anti'
p2504
aS'1 to vaccine'
p2505
aS'induce'
p2506
aS'All reactions'
p2507
aS'get 25'
p2508
aS'device Also'
p2509
aS'HBcAg nasal'
p2510
aS'viral clearance'
p2511
aS'difference'
p2512
aS'similar proportion'
p2513
aS'head tilted'
p2514
aS'any adverse event'
p2515
aS'children became chronic'
p2516
aS'90 days following'
p2517
aS'list'
p2518
aS'prolonged'
p2519
aS'recipients one month'
p2520
aS'were registered Only'
p2521
aS'HBsAg used'
p2522
aS'small'
p2523
aS'infection resolving spontaneously'
p2524
aS'vaccines vaccines administered'
p2525
aS'surveillance methods Concurrent'
p2526
aS'revealed neither'
p2527
aS'antibodies and 25'
p2528
aS'seroprotective antibody titers'
p2529
aS'medical monitor'
p2530
aS'Similarly further assays'
p2531
aS'within 6 months'
p2532
aS'parenteral administered'
p2533
aS'Havana Cuba licensed'
p2534
aS'good safety'
p2535
aS'functioning'
p2536
aS'very distressing'
p2537
aS'enough to cause'
p2538
aS'immunization sera Only'
p2539
aS'10 l per'
p2540
aS'hour after each'
p2541
aS'reconstituted with peripheral'
p2542
aS'Engineering Biotechnology Havana'
p2543
aS'presence'
p2544
aS'samples All'
p2545
aS'behavioral risk factors'
p2546
aS'vomiting'
p2547
aS'events reported'
p2548
aS'animals under'
p2549
aS'HB CIGB'
p2550
aS'excess'
p2551
aS'planned medical consultations'
p2552
aS'nasal drug behavioral'
p2553
aS'significant acute'
p2554
aS'rate exceeded 15'
p2555
aS'immunity against HBV'
p2556
aS'Phase II'
p2557
aS'concluded at day'
p2558
aS'allows'
p2559
aS'after treatment'
p2560
aS'levels of anti'
p2561
aS'vaccine studies'
p2562
aS'novel routes'
p2563
aS'period and severity'
p2564
aS'antibody responses against'
p2565
aS'0 6ml'
p2566
aS'g Miacalcin nasal'
p2567
aS'dose injection'
p2568
aS'chronically infected'
p2569
aS'involved in collection'
p2570
aS'toxicity'
p2571
aS'All subjects received'
p2572
aS'patients resolving'
p2573
aS'more than 400'
p2574
aS'were also collected'
p2575
aS'volunteers Written informed'
p2576
aS'placebo group Individuals'
p2577
aS'pockets enable'
p2578
aS'anosmia nasal'
p2579
aS'immunoenhancing'
p2580
aS'surveillance methods'
p2581
aS'events within'
p2582
aS'commercial recombinant HBcAg'
p2583
aS'immunosuppressive disorders'
p2584
aS'trained'
p2585
aS'calcitonin salmon Novartis'
p2586
aS'mononuclear'
p2587
aS'containing recombinant hepatitis'
p2588
aS'alkaline phosphatase conjugate'
p2589
aS'B cell activator'
p2590
aS'clearly demonstrates'
p2591
aS'l for analysis'
p2592
aS'interval protocol'
p2593
aS'CTL level'
p2594
aS'intervention to prevent'
p2595
aS'received either NASVAC'
p2596
aS'geometric mean antibody'
p2597
aS'available for testing'
p2598
aS'were requested'
p2599
aS'outpatient'
p2600
aS'Drug Quality Control'
p2601
aS'tested'
p2602
aS'anti HBs ELISA'
p2603
aS'were mild self'
p2604
aS'cell dependent'
p2605
aS'Cuba licensed hepatitis'
p2606
aS'drug over'
p2607
aS'administration of successive'
p2608
aS'avoid anterior'
p2609
aS'strong HBV core'
p2610
aS'mean antibody'
p2611
aS'placebo controlled double'
p2612
aS'support further phase'
p2613
aS'l and high'
p2614
aS'nine'
p2615
aS'mostly reported during'
p2616
aS'any symptom'
p2617
aS'well coated'
p2618
aS'fever chills headache'
p2619
aS'volunteer received either'
p2620
aS'include combined'
p2621
aS'antigens Rates'
p2622
aS'group sample size'
p2623
aS'observation period concluded'
p2624
aS'All blood samples'
p2625
aS'potential therapeutic use'
p2626
aS'minimum'
p2627
aS'higher than'
p2628
aS'numbers'
p2629
aS'tract'
p2630
aS'sense'
p2631
aS'HBsAg immunogenicity'
p2632
aS'activated B cells'
p2633
aS'developed antibodies'
p2634
aS'inoculation under sterile'
p2635
aS'against both antigens'
p2636
aS'baseline all participants'
p2637
aS'antibodies against HBsAg'
p2638
aS'fluorigenic substrate'
p2639
aS'defined as concentration'
p2640
aS'multi specific'
p2641
aS'hypo responders'
p2642
aS'titer Anti'
p2643
aS'cases of fever'
p2644
aS'l in such'
p2645
aS'activator'
p2646
aS'routine use'
p2647
aS'plant'
p2648
aS'sandwich'
p2649
aS'percentages were'
p2650
aS'mild No development'
p2651
aS's head tilted'
p2652
aS'known nasally administered'
p2653
aS'true adverse'
p2654
aS'otorhinolaryngologist performed periodical'
p2655
aS'two seroprotected vaccine'
p2656
aS'buffer'
p2657
aS'enables antigens'
p2658
aS'Withdrawal'
p2659
aS'There were also'
p2660
aS'l based'
p2661
aS'results indicated'
p2662
aS'recombinant full length'
p2663
aS'ELISA kits Samples'
p2664
aS'rhinorrhea nasal stuffiness'
p2665
aS'superior to 95'
p2666
aS'chemistries'
p2667
aS'chronically infected patients'
p2668
aS'transient nasal'
p2669
aS'failures included persistently'
p2670
aS'safety and preliminary'
p2671
aS'T cell dependent'
p2672
aS'signs nor'
p2673
aS'enabling activated'
p2674
aS'specific post inoculation'
p2675
aS'group included sneezing'
p2676
aS'cell activator'
p2677
aS'between 18'
p2678
aS'made actively'
p2679
aS'signs'
p2680
aS'HBsAgHBcAg vaccine candidate'
p2681
aS'gratefully acknowledge Enrique'
p2682
aS'20'
p2683
aS'5ml Participants allocated'
p2684
aS'luminal surface'
p2685
aS'UMELISA plates 10'
p2686
aS'nasal immunization'
p2687
aS'moderate adverse'
p2688
aS'detected'
p2689
aS'were available'
p2690
aS'Local site adverse'
p2691
aS'volunteer generating more'
p2692
aS'placebo developed'
p2693
aS'antibody response'
p2694
aS'HBsAg mixed'
p2695
aS'drugs of protein'
p2696
aS'2R'
p2697
aS'effective approach'
p2698
aS'baseline 30 days'
p2699
aS'encouraging'
p2700
aS'medicine toxicology'
p2701
aS'unexpected or severe'
p2702
aS'Immunoassay Center'
p2703
aS'cell pockets enable'
p2704
aS'generating more'
p2705
aS'natural HBsAg subtype'
p2706
aS'g influenza'
p2707
aS'HBcAg Biokit'
p2708
aS'seroprotected vaccine recipients'
p2709
aS'became chronic'
p2710
aS'palate itching rhinorrhea'
p2711
aS'determine mucosal'
p2712
aS'antibodies 17'
p2713
aS'always'
p2714
aS'assistance and helpful'
p2715
aS'Further antigenicity studies'
p2716
aS'Only anti'
p2717
aS'did'
p2718
aS'collection of any'
p2719
aS'obtaining written informed'
p2720
aS'found'
p2721
aS'difficult'
p2722
aS'were collected'
p2723
aS'characterized'
p2724
aS'defects'
p2725
aS'excess over'
p2726
aS'Following administration'
p2727
aS'tilted'
p2728
aS'weight'
p2729
aS'undetectable'
p2730
aS'HBsAg antigen'
p2731
aS'considered statistically significant'
p2732
aS'present formulation Phase'
p2733
aS'temperature 39'
p2734
aS'antibodies Thus most'
p2735
aS'moderate and severe'
p2736
aS'licensed nasal vaccine'
p2737
aS'moderate symptom bothersome'
p2738
aS'20 of healthy'
p2739
aS'volunteers Written'
p2740
aS'Drug Administration'
p2741
aS'permanent disability'
p2742
aS'low responders anti'
p2743
aS'toxicological studies'
p2744
aS'vomiting diarrhea'
p2745
aS'29'
p2746
aS'frequently reported'
p2747
aS'months of study'
p2748
aS'Geometric mean anti'
p2749
aS'study one'
p2750
aS'mucosal irritating potential'
p2751
aS'severe Local site'
p2752
aS'age Volunteers were'
p2753
aS'issue'
p2754
aS'transport antigens'
p2755
aS'renal dialysis'
p2756
aS'each treatment'
p2757
aS'patients or chronic'
p2758
aS'According'
p2759
aS'mild symptom present'
p2760
aS'specialized mechanisms'
p2761
aS'Phase II clinical'
p2762
aS'Nine'
p2763
aS'19 included'
p2764
aS'immunity against HBcAg'
p2765
aS'mucosal blood vessel'
p2766
aS'registered Only two'
p2767
aS'phosphate buffer without'
p2768
aS'allocation'
p2769
aS'antigenic'
p2770
aS'single otorhinolaryngologist performed'
p2771
aS'fever were registered'
p2772
aS'studies HBcAg'
p2773
aS'age Volunteers'
p2774
aS'seroprotective antibody'
p2775
aS'currently licensed'
p2776
aS'g purified'
p2777
aS'accession number X02763'
p2778
aS'Recombinant HBcAg'
p2779
aS'Severe reactions'
p2780
aS'major'
p2781
aS'consultations'
p2782
aS'probability'
p2783
aS'resulting HBcAg'
p2784
aS'0 73 provided'
p2785
aS'reacts with solid'
p2786
aS'Quality Control'
p2787
aS'any clinical'
p2788
aS'detection of total'
p2789
aS'two participants completed'
p2790
aS'eight recipients'
p2791
aS'mouth Two applications'
p2792
aS'including antigen'
p2793
aS'trial no formal'
p2794
aS'mixture of 50g'
p2795
aS'HBsAg significantly'
p2796
aS'cell and antibody'
p2797
aS'threatening'
p2798
aS'least'
p2799
aS'changes in animals'
p2800
aS'Dickinson were filled'
p2801
aS'well documented'
p2802
aS'majority'
p2803
aS'compartment'
p2804
aS'9 sterile'
p2805
aS'chills headache muscle'
p2806
aS'participants needed'
p2807
aS'dose and between'
p2808
aS'general reaction'
p2809
aS'react with antibodies'
p2810
aS'approximately 500DC'
p2811
aS'immunogenicity profile'
p2812
aS'undetectable anti HBs'
p2813
aS'immediate'
p2814
aS'basal'
p2815
aS'neutralization'
p2816
aS'strong HBV'
p2817
aS'study support further'
p2818
aS'Food and Drug'
p2819
aS'defects in dendritic'
p2820
aS'Biokit'
p2821
aS'were mostly'
p2822
aS'against hepatitis'
p2823
aS'kind'
p2824
aS'75 By comparison'
p2825
aS'vial'
p2826
aS'30 Thirty days'
p2827
aS'characterized by electron'
p2828
aS'profile under'
p2829
aS'administered by day'
p2830
aS'vaccine and peptide'
p2831
aS'declare'
p2832
aS'antigen sampling including'
p2833
aS'Cuba All'
p2834
aS'CENATOX'
p2835
aS'HBeAg in saliva'
p2836
aS'immunogenicity Preclinical mouse'
p2837
aS'72hours'
p2838
aS'fixed volume'
p2839
aS'Dawley rats revealed'
p2840
aS'fever were'
p2841
aS'period concluded'
p2842
aS'showing antibody levels'
p2843
aS'glycosylated form HBcAg'
p2844
aS'dendritic'
p2845
aS'categorized'
p2846
aS'0038 All'
p2847
aS'assay anti'
p2848
aS'antibodies against'
p2849
aS'C until'
p2850
aS'virus control Recombinant'
p2851
aS'using similar surveillance'
p2852
aS'immunodominant antigen'
p2853
aS'internal'
p2854
aS'Baseline comparability'
p2855
aS'achieved anti HBs'
p2856
aS'after treatment display'
p2857
aS'specific Th cell'
p2858
aS'Written informed consent'
p2859
aS'added'
p2860
aS'severity mild'
p2861
aS'flu vaccine'
p2862
aS'intensity and 98'
p2863
aS'reach'
p2864
aS'developed antibodies against'
p2865
aS'react'
p2866
aS'commercial ultramicroanalytic enzyme'
p2867
aS'73'
p2868
aS'moderate symptom'
p2869
aS'approved'
p2870
aS'recombinant HBcAg particles'
p2871
aS'given 15 minutes'
p2872
aS'trial Nine participants'
p2873
aS'immunomodulatory effect'
p2874
aS'were healthy'
p2875
aS'reported nasal'
p2876
aS'get 25 seroprotection'
p2877
aS'vaccine Heberbiovac'
p2878
aS'Local adverse'
p2879
aS'graded as severe'
p2880
aS'formulation Sterile'
p2881
aS'recipients one'
p2882
aS'emitted fluorescence'
p2883
aS'authors'
p2884
aS'basal surface'
p2885
aS'aches decreased appetite'
p2886
aS'All sera were'
p2887
aS'attention Serious'
p2888
aS'samples were evaluated'
p2889
aS'candidate administered'
p2890
aS'balanced format'
p2891
aS'other commercial anti'
p2892
aS'impact'
p2893
aS'purity superior'
p2894
aS'parameters'
p2895
aS'64 8IU'
p2896
aS'severe symptoms'
p2897
aS'until use'
p2898
aS'any other nasal'
p2899
aS'basic hematological parameters'
p2900
aS'minutes apart All'
p2901
aS'HBs 10IU'
p2902
aS'prior inoculation'
p2903
aS'surface through'
p2904
aS'Thirty'
p2905
aS'immunogenicity of full'
p2906
aS'antigens by nasal'
p2907
aS'Geometric mean'
p2908
aS'event profile'
p2909
aS'assigned arbitrarily'
p2910
aS'instructed to measure'
p2911
aS'human sera'
p2912
aS'closely'
p2913
aS'male adults between'
p2914
aS'were considered hyper'
p2915
aS'anti HBs protective'
p2916
aS'candidate containing'
p2917
aS'evaluated during'
p2918
aS'State Center'
p2919
aS'HBsAg titer Anti'
p2920
aS'only 30'
p2921
aS'HBs ELISA'
p2922
aS'common'
p2923
aS'rhinorrhea nasal'
p2924
aS'administration also'
p2925
aS'subjects reporting adverse'
p2926
aS'residence time'
p2927
aS'both cases'
p2928
aS'vaccines plant derived'
p2929
aS'plasmid containing'
p2930
aS'Enrique'
p2931
aS'very encouraging taking'
p2932
aS'severe Clinically significant'
p2933
aS'nasal bleeding Solicited'
p2934
aS'Neither'
p2935
aS'trial Nine'
p2936
aS'allowed expiration'
p2937
aS'nasal ulceration'
p2938
aS'97 of adverse'
p2939
aS'kits Samples'
p2940
aS'immunization sera'
p2941
aS'77 recorded'
p2942
aS'currently'
p2943
aS'diluted'
p2944
aS'event There'
p2945
aS'immediate adverse'
p2946
aS'g Miacalcin'
p2947
aS'tolerated safe'
p2948
aS'DC Additionally'
p2949
aS'neither clinical'
p2950
aS'outcomes were'
p2951
aS'corroborates previous findings'
p2952
aS'obtaining written'
p2953
aS'products or immunoglobulin'
p2954
aS'other well'
p2955
aS'study entry'
p2956
aS'8IU l All'
p2957
aS'after vaccine administration'
p2958
aS'nostril were'
p2959
aS'sera Only'
p2960
aS'itching anosmia'
p2961
aS'2000 Among'
p2962
aS'peripheral blood'
p2963
aS'were kept'
p2964
aS'HBV specific immune'
p2965
aS'nucleoprotein in trace'
p2966
aS'headache muscle'
p2967
aS'antibody levels 100IU'
p2968
aS'HBs in sera'
p2969
aS'novel hepatitis'
p2970
aS'immunotherapy'
p2971
aS'became'
p2972
aS'severity Binomial'
p2973
aS'80 90'
p2974
aS'toxicology'
p2975
aS'event rate'
p2976
aS'study products'
p2977
aS'arbitrarily'
p2978
aS'point'
p2979
aS'order to increase'
p2980
aS'protective anti'
p2981
aS'congestion'
p2982
aS'recorded during 90'
p2983
aS'patient with high'
p2984
aS'were reported during'
p2985
aS'populations known'
p2986
aS'high mucosal nasal'
p2987
aS'antibody against'
p2988
aS'multi specific helper'
p2989
aS'vessel'
p2990
aS'candidate formulated'
p2991
aS'rabbits with induction'
p2992
aS'6 months'
p2993
aS'participants received'
p2994
aS'between 24h'
p2995
aS'venipuncture for measurement'
p2996
aS'doctor s visits'
p2997
aS'height between vaccine'
p2998
aS'strategy'
p2999
aS'reduction'
p3000
aS'ensured'
p3001
aS'All anti HBs'
p3002
aS'vaccine recipients according'
p3003
aS'detection of cellular'
p3004
aS'allows interaction'
p3005
aS'annoying'
p3006
aS'abnormalities in clinical'
p3007
aS'one hyper responder'
p3008
aS'trained physician'
p3009
aS'both antigens'
p3010
aS'study in 19'
p3011
aS'Sterile physiologic saline'
p3012
aS'occurred during'
p3013
aS'acemannan Whether'
p3014
aS'liver'
p3015
aS'titers of more'
p3016
aS'Preclinical toxicological'
p3017
aS'developments'
p3018
aS'screening visit'
p3019
aS'highest'
p3020
aS'cause'
p3021
aS'resulting'
p3022
aS'solid'
p3023
aS'safe and immunogenic'
p3024
aS'enrollment'
p3025
aS'coated with commercial'
p3026
aS'well known'
p3027
aS'vaccine allocation'
p3028
aS'antibody tests against'
p3029
aS'behavior'
p3030
aS'Exposure'
p3031
aS'resolving within 72h'
p3032
aS'Becton Dickinson were'
p3033
aS'Furthermore local'
p3034
aS'nurse sprayed'
p3035
aS'37'
p3036
aS'subjects signed'
p3037
aS'volunteers were aware'
p3038
aS'binding'
p3039
aS'study after'
p3040
aS'production facilities'
p3041
aS'display strong'
p3042
aS'immunomodulatory'
p3043
aS'during 90'
p3044
aS'commonly'
p3045
aS'recipients achieved anti'
p3046
aS'seroprotected vaccine'
p3047
aS'reach 75'
p3048
aS'alone'
p3049
aS'aches'
p3050
aS'rate increased'
p3051
aS'estimate'
p3052
aS'reporting of adverse'
p3053
aS'fashion on code'
p3054
aS'studies were'
p3055
aS'authors thank'
p3056
aS'nausea vomiting diarrhea'
p3057
aS'weak HBV specific'
p3058
aS'negative result'
p3059
aS'conflict'
p3060
aS'influenza nasal'
p3061
aS'g HBsAg mixed'
p3062
aS'7 of them'
p3063
aS'performed periodical examinations'
p3064
aS'Miacalcin'
p3065
aS'nasally parenteral administered'
p3066
aS'48hours on administration'
p3067
aS'conducted in Sprague'
p3068
aS'antibody titers against'
p3069
aS'mild self limiting'
p3070
aS'severe Severe reactions'
p3071
aS'systemic reactions 71'
p3072
aS'HBcAg Individuals were'
p3073
aS'did not increase'
p3074
aS'older'
p3075
aS'percentages'
p3076
aS'negative for HBsAg'
p3077
aS'responder volunteer'
p3078
aS'sera Briefly UMELISA'
p3079
aS'clinically significant'
p3080
aS'achieved antibody'
p3081
aS'polyclonal'
p3082
aS'anti HBs 100IU'
p3083
aS'negative immunomodulatory'
p3084
aS'entry'
p3085
aS'clearance'
p3086
aS'Quality'
p3087
aS'adverse events 58'
p3088
aS'carrier state'
p3089
aS'nucleoprotein'
p3090
aS'test for proportions'
p3091
aS'CECMED'
p3092
aS'administered using'
p3093
aS'given 15'
p3094
aS'sera were available'
p3095
aS'devices and methodologies'
p3096
aS'competitive'
p3097
aS'cells transport antigens'
p3098
aS'administration enables antigens'
p3099
aS'against HBsAg 10IU'
p3100
aS'rate exceeded'
p3101
aS'useful'
p3102
aS'recombinant HBsAg subtype'
p3103
aS'Written informed'
p3104
aS'immunoenzymatic assay'
p3105
aS'HBs ELISA kits'
p3106
aS'nasal route showing'
p3107
aS'schedule Following'
p3108
aS'corroborates'
p3109
aS'added reacting'
p3110
aS'specific immune response'
p3111
aS'g of HBcAg'
p3112
aS'12h post immunization'
p3113
aS'estimate each'
p3114
aS'same volume'
p3115
aS'immediate adverse events'
p3116
aS'increase in frequency'
p3117
aS'transparent liquid'
p3118
aS'doses Local adverse'
p3119
aS'liver failure'
p3120
aS'format'
p3121
aS'situation'
p3122
aS'included fever chills'
p3123
aS'HBcAg nucleic acids'
p3124
aS'support further'
p3125
aS'Finlay Hospital Havana'
p3126
aS'showing antibody'
p3127
aS'purified recombinant full'
p3128
aS'0 05'
p3129
aS'allocated to placebo'
p3130
aS'13 excess over'
p3131
aS'diseases immunosuppressive'
p3132
aS'reacting'
p3133
aS'adjustments were made'
p3134
aS'respect to anti'
p3135
aS'signal'
p3136
aS'hospitalizations were also'
p3137
aS'only comprises'
p3138
aS'reported in recipients'
p3139
aS'developed anti'
p3140
aS'over nasally parenteral'
p3141
aS'primary APCs'
p3142
aS'allocation All aspects'
p3143
aS'conducted to characterize'
p3144
aS'Serious adverse'
p3145
aS'low responders'
p3146
aS'nausea vomiting'
p3147
aS'Dawley'
p3148
aS'steroid anti'
p3149
aS'controlled double blinded'
p3150
aS'normal functioning may'
p3151
aS'neutralization using'
p3152
aS'delivered'
p3153
aS'reconstituted'
p3154
aS'rates of seroprotection'
p3155
aS'incubated with samples'
p3156
aS'interest to declare'
p3157
aS'fatal or life'
p3158
aS'nasal bleeding'
p3159
aS'particle to more'
p3160
aS'derived vaccines'
p3161
aS'immunization Withdrawal'
p3162
aS'any immediate'
p3163
aS'nose'
p3164
aS'hyper responder volunteer'
p3165
aS'patient'
p3166
aS'fifth vaccine dose'
p3167
aS'dose at time'
p3168
aS'matched pre'
p3169
aS'treatment display strong'
p3170
aS'vaccine and placebo'
p3171
aS'Dickinson Depending'
p3172
aS'helper and cytotoxic'
p3173
aS'reasonably immunogenic'
p3174
aS'Chronic HBV'
p3175
aS'hepatitis B surface'
p3176
aS'saliva from one'
p3177
aS'body system Adverse'
p3178
aS'after inoculation'
p3179
aS'apparent abnormalities'
p3180
aS'range'
p3181
aS'male adult'
p3182
aS'4 C until'
p3183
aS'remaining 19'
p3184
aS'successive vaccine'
p3185
aS'immunization for any'
p3186
aS'comparison licensed HBV'
p3187
aS'annoying may'
p3188
aS'anti HBs 10IU'
p3189
aS'assay for qualitative'
p3190
aS'candidate developed'
p3191
aS'formal sample'
p3192
aS'antigen uptake'
p3193
aS'Only two moderate'
p3194
aS'recent exposure'
p3195
aS'all participants prior'
p3196
aS'reactions 71'
p3197
aS'enhancement of antiviral'
p3198
aS'computer'
p3199
aS'luminal'
p3200
aS'long'
p3201
aS'after obtaining'
p3202
aS'hepatocellular carcinoma'
p3203
aS'there were'
p3204
aS'time 37'
p3205
aS'result On completion'
p3206
aS'general reaction category'
p3207
aS'self limited'
p3208
aS'two moderate'
p3209
aS'nor induced'
p3210
aS'virus after'
p3211
aS'registered'
p3212
aS'19 participants were'
p3213
aS'X02763 HBsAg'
p3214
aS'Severe'
p3215
aS'calcitonin salmon'
p3216
aS'injection'
p3217
aS'HBs only'
p3218
aS'further immunogenicity'
p3219
aS'group Sneezing palate'
p3220
aS'such as older'
p3221
aS'commonly reported nasal'
p3222
aS'Heberbiovac HB CIGB'
p3223
aS'seroconversion after'
p3224
aS'given via'
p3225
aS'co administered HBsAg'
p3226
aS'criterion for protection'
p3227
aS'increased to 75'
p3228
aS'associated'
p3229
aS'Local site reactions'
p3230
aS'minutes'
p3231
aS'administration of each'
p3232
aS'participants were randomly'
p3233
aS'4 pre existing'
p3234
aS'continuous variables Adverse'
p3235
aS'quantification'
p3236
aS'generated list'
p3237
aS'second vaccine'
p3238
aS'immunosorbent assay ELISA'
p3239
aS'microscopy EM analysis'
p3240
aS'mouse studies'
p3241
aS'carcinoma'
p3242
aS'e g Miacalcin'
p3243
aS'amounts'
p3244
aS'screen failures'
p3245
aS'studied dose'
p3246
aS'over systemic'
p3247
aS'transport'
p3248
aS'visits and hospitalizations'
p3249
aS'gratefully acknowledge'
p3250
aS'HBcAg Individuals'
p3251
aS'fourth immunization Withdrawal'
p3252
aS'positive response'
p3253
aS'most commonly'
p3254
aS'15 participants'
p3255
aS'activity of HBcAg'
p3256
aS'tests 4 pre'
p3257
aS'generated'
p3258
aS'secondary outcomes'
p3259
aS'resulting HBcAg had'
p3260
aS'further assays'
p3261
aS'nucleic acids bound'
p3262
aS'Participants were'
p3263
aS'immunogenic in healthy'
p3264
aS'samples All anti'
p3265
aS'mucosal immune system'
p3266
aS'methodologies'
p3267
aS'fluorescence'
p3268
aS'volumes of samples'
p3269
aS'placebo solution All'
p3270
aS'network of approximately'
p3271
aS'high HBsAg titer'
p3272
aS'recorded adverse events'
p3273
aS'group No unexpected'
p3274
aS'HBs only 30'
p3275
aS'study personnel'
p3276
aS'international'
p3277
aS'developed seroprotective'
p3278
aS'having'
p3279
aS'time of immunization'
p3280
aS'code'
p3281
aS'partial'
p3282
aS'resolving acute'
p3283
aS'group remained positive'
p3284
aS's head'
p3285
aS'existing'
p3286
aS'fourth dose'
p3287
aS'Immunoassay'
p3288
aS'Biotechnology Havana'
p3289
aS'were not substantially'
p3290
aS'third dose'
p3291
aS'mild symptom'
p3292
aS'consultations or doctor'
p3293
aS'mild moderate'
p3294
aS'l per nostril'
p3295
aS'resolving within'
p3296
aS'young'
p3297
aS'between study'
p3298
aS'chronic infection resolving'
p3299
aS'excluded'
p3300
aS'fatal'
p3301
aS'One recipient'
p3302
aS'remained positive'
p3303
aS'adjuvants gene vaccine'
p3304
aS'HBV vaccine Heberbiovac'
p3305
aS'random'
p3306
aS'most frequent'
p3307
aS'group 59'
p3308
aS'vaccine allocation All'
p3309
aS'25 seroprotection'
p3310
aS'venipuncture'
p3311
aS'HBs 10 100IU'
p3312
aS'state of unresponsiveness'
p3313
aS'vaccine and were'
p3314
aS'mucosal immunization further'
p3315
aS'electron'
p3316
aS'cellular'
p3317
aS'functional defects'
p3318
aS'young adults 30'
p3319
aS'cell and cytotoxic'
p3320
aS'100IU l Sera'
p3321
aS'nausea'
p3322
aS'recombinant Heberbiovac HB'
p3323
aS'entire'
p3324
aS'core HBc specific'
p3325
aS'dose of HBsAg'
p3326
aS'induced local damage'
p3327
aS'peripheral blood mononuclear'
p3328
aS'HBsAg subtype CIGB'
p3329
aS'race'
p3330
aS'7 years'
p3331
aS'Adverse events did'
p3332
aS'levels 100IU'
p3333
aS'concluded'
p3334
aS'CIGB production facilities'
p3335
aS'number X02763 HBsAg'
p3336
aS'events as well'
p3337
aS'length recombinant'
p3338
aS'bleeding'
p3339
aS'distressing interference'
p3340
aS'kept under observation'
p3341
aS'responder volunteer generating'
p3342
aS'State'
p3343
aS'included persistently abnormal'
p3344
aS'study No cases'
p3345
aS'surface network'
p3346
aS'transformed previously'
p3347
aS'group sample'
p3348
aS'limiting resolving within'
p3349
aS'anti HBV'
p3350
aS'cutaneous'
p3351
aS'clinical data'
p3352
aS'post immunization Solicited'
p3353
aS'were similar'
p3354
aS'HBV specific'
p3355
aS'consistently'
p3356
aS'code labeled matched'
p3357
aS'white race'
p3358
aS'values'
p3359
aS'hematology values were'
p3360
aS'stuffiness or congestion'
p3361
aS'thin'
p3362
aS'body'
p3363
aS'developed seroprotective antibody'
p3364
aS'doses Adverse'
p3365
aS'status after'
p3366
aS'years range 18'
p3367
aS'other particulate antigens'
p3368
aS'volunteers inoculated'
p3369
aS'strain W3110'
p3370
aS'other symptoms'
p3371
aS'different than'
p3372
aS'functioning may'
p3373
aS'size nine participants'
p3374
aS'vaccine administration'
p3375
aS'consideration'
p3376
aS'any study procedure'
p3377
aS'Participants were kept'
p3378
aS'compromised'
p3379
aS'39'
p3380
aS'38'
p3381
aS'PBMCs'
p3382
aS'involved'
p3383
aS'distribution point'
p3384
aS'fully demonstrated'
p3385
aS'total serum'
p3386
aS'volume of 125'
p3387
aS'vaccines or had'
p3388
aS'vial contained'
p3389
aS'healthy young'
p3390
aS'anti HBs equal'
p3391
aS'examinations'
p3392
aS'formulated'
p3393
aS'all other reactions'
p3394
aS'fluorescent substrate'
p3395
aS'molecule as revealed'
p3396
aS'titer Anti HBs'
p3397
aS'outcomes'
p3398
aS'HBsAg immunogenicity Preclinical'
p3399
aS'comparison with other'
p3400
aS'unresponsiveness'
p3401
aS'sensitivity to any'
p3402
aS'4 pre'
p3403
aS'plant derived'
p3404
aS'each treatment group'
p3405
aS'acute or chronic'
p3406
aS'neither irritating'
p3407
aS'results of preclinical'
p3408
aS'inoculation adverse reactions'
p3409
aS'severe Severe'
p3410
aS'anti inflammatory'
p3411
aS'chemistry and basic'
p3412
aS'duplicate'
p3413
aS'examination'
p3414
aS'days post immunization'
p3415
aS'secondary outcomes were'
p3416
aS'HBcAg CIGB Havana'
p3417
aS'anti inflammatory analgesics'
p3418
aS'first inoculation using'
p3419
aS'10 100IU'
p3420
aS'computer generated'
p3421
aS'Miacalcin nasal'
p3422
aS'occurred'
p3423
aS'transient'
p3424
aS'history of sensitivity'
p3425
aS'rabbit'
p3426
aS'vaccine candidate formulated'
p3427
aS'local reaction'
p3428
aS'nasal conditions'
p3429
aS'randomized and received'
p3430
aS'evident and corroborates'
p3431
aS'animals'
p3432
aS'known nasally'
p3433
aS'immunodominant'
p3434
aS'until use Nasal'
p3435
aS'subtype CIGB'
p3436
aS'Solid phase antigen'
p3437
aS'were closely assessed'
p3438
aS'mucosal blood'
p3439
aS'field'
p3440
aS'positive for anti'
p3441
aS'profile Recent advances'
p3442
aS'Miacalcin nasal spray'
p3443
aS'pre study'
p3444
aS'study drug'
p3445
aS'administered through novel'
p3446
aS'calculation'
p3447
aS'adults and 80'
p3448
aS'proportions'
p3449
aS'symptom present'
p3450
aS'Written'
p3451
aS'anosmia nasal ulceration'
p3452
aS'mononuclear cells PBMCs'
p3453
aS'samples Solid phase'
p3454
aS'particles'
p3455
aS'similar proportion hypo'
p3456
aS'0 2IU'
p3457
aS'doses Adverse events'
p3458
aS'irritating potential'
p3459
aS'during 90 applied'
p3460
aS'vessel status'
p3461
aS'dependent'
p3462
aS'90 day'
p3463
aS'adapted'
p3464
aS'candidate showed'
p3465
aS'using similar'
p3466
aS'hypothesis testing'
p3467
aS'also collected'
p3468
aS'developed anti HBs'
p3469
aS'6ml'
p3470
aS'any local reaction'
p3471
aS'43 subjects'
p3472
aS'discomfort'
p3473
aS'limiting and disappeared'
p3474
aS'without adjuvants'
p3475
aS'any immediate adverse'
p3476
aS'Furthermore participants were'
p3477
aS'recipients as early'
p3478
aS'vaccine doses Adverse'
p3479
aS'binding of HBsAg'
p3480
aS'mice and rabbits'
p3481
aS'study were'
p3482
aS'even without adjuvants'
p3483
aS'One'
p3484
aS'Furthermore participants'
p3485
aS'Nasal administration enables'
p3486
aS'study clearly demonstrates'
p3487
aS'adjustments were'
p3488
aS'competitive sequential'
p3489
aS'Local adverse events'
p3490
aS'abnormalities visualized'
p3491
aS'significant events were'
p3492
aS'preclinical'
p3493
aS'produced'
p3494
aS'including'
p3495
aS'units per liter'
p3496
aS'All reactions were'
p3497
aS'administered by intranasal'
p3498
aS'chemistry'
p3499
aS'white race predominated'
p3500
aS'superior'
p3501
aS'mice with full'
p3502
aS'absent mild symptom'
p3503
aS'consent Individuals'
p3504
aS'reactions combined'
p3505
aS'each rate'
p3506
aS'were self'
p3507
aS'70IU'
p3508
aS'antigen sampling'
p3509
aS'specific active'
p3510
aS'g purified recombinant'
p3511
aS'accession number'
p3512
aS'physicians'
p3513
aS'study nurse sprayed'
p3514
aS'mechanisms'
p3515
aS'assessed by Fisher'
p3516
aS'prophylactic vaccines plant'
p3517
aS'Binomial distribution'
p3518
aS'Solid'
p3519
aS'years range'
p3520
aS'consent and underwent'
p3521
aS'symptom bothersome discomfort'
p3522
aS'functional'
p3523
aS'licensed nasal flu'
p3524
aS'interference with usual'
p3525
aS'two 25'
p3526
aS'study group remained'
p3527
aS'documented'
p3528
aS'high HBsAg'
p3529
aS'predominated over systemic'
p3530
aS'specific active immunotherapy'
p3531
aS'vaccine antigens NASVAC'
p3532
aS'adverse event There'
p3533
aS'route of immunization'
p3534
aS'participants during'
p3535
aS'epistaxis were'
p3536
aS'Biokit Barcelona'
p3537
aS'systemic adverse effects'
p3538
aS'induced serum'
p3539
aS'after immunization'
p3540
aS'determine mucosal irritating'
p3541
aS'blood vessel'
p3542
aS'any adjuvant'
p3543
aS'estimates and 95'
p3544
aS'clinically significant acute'
p3545
aS'core HBc'
p3546
aS'Thirty days'
p3547
aS'cell responses'
p3548
aS'profile under routine'
p3549
aS'Cuba licensed'
p3550
aS'inoculation adverse'
p3551
aS'exceeded'
p3552
aS'80'
p3553
aS'first dose'
p3554
aS'access Furthermore local'
p3555
aS'were given via'
p3556
aS'self limited HBV'
p3557
aS'rez'
p3558
aS'older individuals renal'
p3559
aS'clinical chemistry'
p3560
aS'other well known'
p3561
aS'l seroprotection percentage'
p3562
aS'controlled double'
p3563
aS'include'
p3564
aS'third vaccine dose'
p3565
aS'confirmed in further'
p3566
aS'medical attention Serious'
p3567
aS'formulation and placebo'
p3568
aS'first inoculation Blood'
p3569
aS'solid phase'
p3570
aS'reacts'
p3571
aS'HBV chronically'
p3572
aS'nasal spray device'
p3573
aS'intranasal route'
p3574
aS'serum antibody responses'
p3575
aS'group observation'
p3576
aS'performed however each'
p3577
aS'study procedure'
p3578
aS'70IU l One'
p3579
aS'mean age'
p3580
aS'candidate tested'
p3581
aS'backwards'
p3582
aS'mucosal immune'
p3583
aS'Sprague Dawley rats'
p3584
aS'after obtaining written'
p3585
aS'against HBV infection'
p3586
aS'HBs antibodies'
p3587
aS'e g influenza'
p3588
aS'event There were'
p3589
aS'chills'
p3590
aS'total anti HBc'
p3591
aS'were needed'
p3592
aS'plates 10'
p3593
aS'length HBcAg CIGB'
p3594
aS'sera block antigenic'
p3595
aS'rabbit anti'
p3596
aS'Administration'
p3597
aS'showed seroconversion against'
p3598
aS'spray devices Accuspray'
p3599
aS'58'
p3600
aS'planned medical'
p3601
aS'C terminal region'
p3602
aS'vaccine only comprises'
p3603
aS'mucosal nasal immunogenicity'
p3604
aS'reporting specific'
p3605
aS'promoter'
p3606
aS'antigenicity'
p3607
aS'reactions were defined'
p3608
aS'immunization Solicited adverse'
p3609
aS'systemic immunity elicited'
p3610
aS'discomfort enough'
p3611
aS'adult volunteers'
p3612
aS'antigens to access'
p3613
aS'analgesics non planned'
p3614
aS'0 0038'
p3615
aS'after vaccine'
p3616
aS'report in humans'
p3617
aS'pre existing'
p3618
aS'HBcAg to HBsAg'
p3619
aS'Volunteers were recruited'
p3620
aS'day period'
p3621
aS'1 hour after'
p3622
aS'limitations explained'
p3623
aS'inoculation Adverse events'
p3624
aS'flu vaccine using'
p3625
aS'Novartis'
p3626
aS'placebo developed antibodies'
p3627
aS'obtained by venipuncture'
p3628
aS'screening regarding'
p3629
aS'institution'
p3630
aS'independent antigen'
p3631
aS'blinded study'
p3632
aS'observed'
p3633
aS'vaccine studies HBcAg'
p3634
aS'nasal HBsAg'
p3635
aS'HBcAg nasal vaccine'
p3636
aS'size nine'
p3637
aS'obtained from all'
p3638
aS'any component'
p3639
aS'assays'
p3640
aS'consent Individuals were'
p3641
aS'each subject'
p3642
aS'calcitonin'
p3643
aS'salmon Novartis'
p3644
aS'elicit seroconversion'
p3645
aS'sera Only anti'
p3646
aS'distribution point estimates'
p3647
aS'cells transport'
p3648
aS'phase II'
p3649
aS'clinical studies'
p3650
aS'cytoplasm'
p3651
aS'them were requested'
p3652
aS'apart All'
p3653
aS'5 More'
p3654
aS'protective anti HBs'
p3655
aS'prevent permanent'
p3656
aS'derived vaccines vaccines'
p3657
aS'events included anterior'
p3658
aS'22nm'
p3659
aS'standard parenteral'
p3660
aS'first in human'
p3661
aS'headache both'
p3662
aS'HBcAg nucleic'
p3663
aS'HBcAg combined formulations'
p3664
aS'After'
p3665
aS'titers around 70IU'
p3666
aS'Center Havana Cuba'
p3667
aS'M cell pockets'
p3668
aS'well as hypo'
p3669
aS'chronic diseases'
p3670
aS'candidate were undertaken'
p3671
aS'unresponsiveness characteristic'
p3672
aS'were not available'
p3673
aS'worldwide'
p3674
aS'II clinical'
p3675
aS'injection and up'
p3676
aS'provided to participants'
p3677
aS'II studies'
p3678
aS'dose to achieve'
p3679
aS'inflammatory Th1 response'
p3680
aS'conditions occurred'
p3681
aS'antigens with DC'
p3682
aS'digestive'
p3683
aS'eight'
p3684
aS'posterior nasal dripping'
p3685
aS'nuisance'
p3686
aS'total dose'
p3687
aS'treatment group observation'
p3688
aS'HBsAg exploiting'
p3689
aS'events were tabulated'
p3690
aS'100 of vaccine'
p3691
aS'chronic patients'
p3692
aS'consequences'
p3693
aS'95 purity'
p3694
aS'further phase'
p3695
aS'schedule formulation'
p3696
aS'modulatory effect'
p3697
aS'headache both reports'
p3698
aS'hour after vaccine'
p3699
aS'immunotherapy in HBV'
p3700
aS'available for screening'
p3701
aS'125l per nostril'
p3702
aS'findings'
p3703
aS'comparison licensed'
p3704
aS'0038'
p3705
aS'developments to boost'
p3706
aS'local adverse event'
p3707
aS'negative immunomodulatory effect'
p3708
aS'immunopotentiating'
p3709
aS'participants completed'
p3710
aS'visualized'
p3711
aS'examinations with visualization'
p3712
aS'considered hyper'
p3713
aS'year 2000'
p3714
aS'Briefly anti'
p3715
aS'fourth immunization'
p3716
aS'placebo group Sneezing'
p3717
aS'Organization there'
p3718
aS'pre study screening'
p3719
aS'events between study'
p3720
aS'tolerance All'
p3721
aS'reporting of nasal'
p3722
aS'rash'
p3723
aS'including antigen uptake'
p3724
aS'under routine'
p3725
aS'most moderate symptom'
p3726
aS'vaccine such'
p3727
aS'achieve'
p3728
aS'approximately 500DC mm'
p3729
aS'C until use'
p3730
aS'center randomized placebo'
p3731
aS'peptide'
p3732
aS'28nm'
p3733
aS'g nasal'
p3734
aS'Whether'
p3735
aS'adults in order'
p3736
aS'disappeared within 72hours'
p3737
aS'severe symptoms very'
p3738
aS'were reported more'
p3739
aS'sterile phosphate buffer'
p3740
aS'had clinically significant'
p3741
aS'patients and immune'
p3742
aS'samples Solid'
p3743
aS'vaccine formulation consisting'
p3744
aS'antibody tests'
p3745
aS'given via nasal'
p3746
aS'anti HBc alkaline'
p3747
aS'baseline all'
p3748
aS'strong polyclonal'
p3749
aS'approach'
p3750
aS'assay ELISA'
p3751
aS'exceeded 15'
p3752
aS'samples were collected'
p3753
aS'hyper responder 100IU'
p3754
aS'phosphatase conjugate'
p3755
aS'potent immunogen even'
p3756
aS'fixed'
p3757
aS'site reactions were'
p3758
aS'e g nasal'
p3759
aS'derived recombinant HBsAg'
p3760
aS'study support'
p3761
aS'screening regarding chemical'
p3762
aS'acceptable local'
p3763
aS'humans'
p3764
aS'trace amounts'
p3765
aS'other reactions combined'
p3766
aS'HBsAg in mice'
p3767
aS'clinical adverse'
p3768
aS'display strong polyclonal'
p3769
aS'carriers of hepatitis'
p3770
aS'HBsAg significantly increases'
p3771
aS'sample size calculation'
p3772
aS'B cell'
p3773
aS'days All'
p3774
aS'digestive tract'
p3775
aS'HBV chronic'
p3776
aS'included anterior'
p3777
aS'cytokine response'
p3778
aS'HBs protective'
p3779
aS'investigators'
p3780
aS'any other symptoms'
p3781
aS'routine'
p3782
aS'were measured'
p3783
aS'cells to work'
p3784
aS'bothersome discomfort enough'
p3785
aS'recombinant hepatitis'
p3786
aS'dendritic cell populations'
p3787
aS'electron microscopy'
p3788
aS'size calculation'
p3789
aS'local reaction category'
p3790
aS'emitted'
p3791
aS'disorders or medication'
p3792
aS'immunization nor'
p3793
aS'single nasal'
p3794
aS'anti HBs alkaline'
p3795
aS'hypothesis'
p3796
aS'failure and hepatocellular'
p3797
aS'successive vaccine doses'
p3798
aS'responses against both'
p3799
aS'had no history'
p3800
aS'Also chronic HBV'
p3801
aS'phase II studies'
p3802
aS'nuisance at most'
p3803
aS'Individuals of white'
p3804
aS'parenteral HBV vaccine'
p3805
aS'taking'
p3806
aS'acknowledge'
p3807
aS'both reports'
p3808
aS'EM analysis Further'
p3809
aS'responder 100IU'
p3810
aS'anti HBs UMELISA'
p3811
aS'itching anosmia nasal'
p3812
aS'HBsAg or HBcAg'
p3813
aS'otorhinolaryngologist performed'
p3814
aS'site reactions'
p3815
aS'5 of seroprotected'
p3816
aS'Toxicology and Carlos'
p3817
aS'were estimated'
p3818
aS'animal studies'
p3819
aS'17 and inability'
p3820
aS'candidate demonstrated seroconversion'
p3821
aS'adverse events within'
p3822
aS'include combined prophylactic'
p3823
aS'posterior dripping'
p3824
aS'fact along'
p3825
aS'study clearly'
p3826
aS'Finally'
p3827
aS'administration enables'
p3828
aS'adults Local site'
p3829
aS'seroprotection percentage anti'
p3830
aS'immunity Nasal'
p3831
aS'human clinical trial'
p3832
aS'rates of local'
p3833
aS'methods Concurrent'
p3834
aS'trial were closely'
p3835
aS'one hyper'
p3836
aS'mucosal irritating'
p3837
aS'sequential immunoenzymatic'
p3838
aS'statistical analysis There'
p3839
aS'activator enabling activated'
p3840
aS'years There were'
p3841
aS'kept under'
p3842
aS'3 and epistaxis'
p3843
aS'days following'
p3844
aS'Research Ethics'
p3845
aS'monoclonal'
p3846
aS'muscle aches'
p3847
aS'dripping nasal'
p3848
aS'Drug Quality'
p3849
aS'detection of IgA'
p3850
aS'comprising HBsAg'
p3851
aS'successive reaction'
p3852
aS'sponsor institution Five'
p3853
aS'headache muscle aches'
p3854
aS'decreased'
p3855
aS'labeled matched'
p3856
aS'one month after'
p3857
aS'acute hepatitis'
p3858
aS'virus anti HBs'
p3859
aS'adverse events between'
p3860
aS'secretion of HBeAg'
p3861
aS'multi'
p3862
aS'hepatocellular'
p3863
aS'8 of vaccine'
p3864
aS'reported among individuals'
p3865
aS'statistical analysis'
p3866
aS'spray devices'
p3867
aS'other nasal drug'
p3868
aS'expiration'
p3869
aS'attention or severe'
p3870
aS'preliminary immunogenicity'
p3871
aS'systemic reactions'
p3872
aS'five vaccine doses'
p3873
aS'helper'
p3874
aS'Cuba and 50'
p3875
aS'inoculation using'
p3876
aS'cutaneous rash'
p3877
aS'completed'
p3878
aS'90 applied'
p3879
aS'mucosal adjuvant'
p3880
aS'specific immune'
p3881
aS'interference with normal'
p3882
aS'visualized in vaccine'
p3883
aS'symptoms very distressing'
p3884
aS'dual'
p3885
aS'random numbers'
p3886
aS'Rates of adverse'
p3887
aS'day 30 Thirty'
p3888
aS'Geometric'
p3889
aS'compartment protected'
p3890
aS'prior to any'
p3891
aS'blood screening'
p3892
aS'recording of adverse'
p3893
aS'supported'
p3894
aS'severe Local'
p3895
aS'infrequent Adverse'
p3896
aS'were given 15'
p3897
aS'abnormal baseline'
p3898
aS'units'
p3899
aS'formulations in healthy'
p3900
aS'further phase II'
p3901
aS'group No subjects'
p3902
aS'adults 30 days'
p3903
aS'antibody level'
p3904
aS'around 70IU'
p3905
aS'85 5 More'
p3906
aS'S protein'
p3907
aS'tolerated and reasonably'
p3908
aS'29 7 years'
p3909
aS'revealed neither clinical'
p3910
aS'placebo solution'
p3911
aS'administration of HBcAg'
p3912
aS'sera block'
p3913
aS'reactions were combined'
p3914
aS'international units'
p3915
aS'formulation in each'
p3916
aS'administration comprising'
p3917
aS'center'
p3918
aS'difficult to access'
p3919
aS'fully'
p3920
aS'Conversely'
p3921
aS'were tabulated'
p3922
aS'24h and 72h'
p3923
aS'failures'
p3924
aS'Chronic HBV infection'
p3925
aS'personnel'
p3926
aS'comparisons'
p3927
aS'muscle'
p3928
aS'applied doses 85'
p3929
aS'usual'
p3930
aS'subjects reporting specific'
p3931
aS'Baseline'
p3932
aS'77 adverse events'
p3933
aS'HBsAg HBcAg combined'
p3934
aS'Immunoassay Center Havana'
p3935
aS'recipients of other'
p3936
aS'subjects withdrew'
p3937
aS'salmon'
p3938
aS'HBcAg at day'
p3939
aS'were no differences'
p3940
aS'secreted protein'
p3941
aS'impaired'
p3942
aS'Barcelona Spain'
p3943
aS'inoculations'
p3944
aS'group observation period'
p3945
aS'variables Adverse'
p3946
aS'other licensed nasal'
p3947
aS'devices Accuspray Becton'
p3948
aS'achieved anti'
p3949
aS'10 of adults'
p3950
aS'immunoenhancing activity'
p3951
aS'were considered'
p3952
aS'values were found'
p3953
aS'transparent'
p3954
aS'antiviral therapies'
p3955
aS'reasons'
p3956
aS'potent B cell'
p3957
aS'l One'
p3958
aS'Despite'
p3959
aS'lymphocytes'
p3960
aS'severe Clinically'
p3961
aS'matched'
p3962
aS'decreased appetite nausea'
p3963
aS'inoculation and were'
p3964
aS'closely assessed'
p3965
aS'increased'
p3966
aS'tolerated and induced'
p3967
aS'immunization with hepatitis'
p3968
aS'mild self'
p3969
aS'were aware'
p3970
aS'9 sterile saline'
p3971
aS'increases'
p3972
aS'Food'
p3973
aS'recipients achieved'
p3974
aS'UMELISA plates'
p3975
aS'values were'
p3976
aS'each immunization'
p3977
aS'Further antigenicity'
p3978
aS'three doses'
p3979
aS'significant no adjustments'
p3980
aS'Sneezing palate'
p3981
aS'most moderate'
p3982
aS'mucosal immunogenicity'
p3983
aS'HB CIGB Havana'
p3984
aS'exploiting'
p3985
aS'qualitative'
p3986
aS'considered statistically'
p3987
aS'differences between vaccine'
p3988
aS'hosts'
p3989
aS'l per well'
p3990
aS'days post'
p3991
aS'infection In vaccine'
p3992
aS'Preclinical mouse'
p3993
aS'clearly evident'
p3994
aS'therapeutic'
p3995
aS'products were stored'
p3996
aS'significant persistent'
p3997
aS'hospitalizations'
p3998
aS'placebo received'
p3999
aS'underwent'
p4000
aS'schedule In two'
p4001
aS'balanced format using'
p4002
aS'baseline biochemistry'
p4003
aS'events were mostly'
p4004
aS'Dickinson were'
p4005
aS'effects predominated'
p4006
aS'relevant for virus'
p4007
aS'least one adverse'
p4008
aS'present formulation'
p4009
aS'cell responses against'
p4010
aS'reported nasal adverse'
p4011
aS'chronic carriage'
p4012
aS'monitored'
p4013
aS'consistently demonstrated'
p4014
aS'demonstrates'
p4015
aS'avoid'
p4016
aS'serum clinical'
p4017
aS'presenting cells APCs'
p4018
aS'were filled'
p4019
aS'candidate developed seroprotective'
p4020
aS'18 45'
p4021
aS'HBcAg immunomodulation'
p4022
aS'formulation and device'
p4023
aS'itching palate'
p4024
aS'head tilted backwards'
p4025
aS'bothersome discomfort'
p4026
aS'percentage anti HBc'
p4027
aS'limitations'
p4028
aS'probability of detecting'
p4029
aS'coated'
p4030
aS'used Genbank accession'
p4031
aS'length recombinant HBcAg'
p4032
aS'Center for Drug'
p4033
aS'outpatient basis'
p4034
aS'samples and reagents'
p4035
aS'6 13'
p4036
aS'adverse reaction'
p4037
aS'mucosal immunization'
p4038
aS'other developed anti'
p4039
aS'HBc UMELISA Immunoassay'
p4040
aS'stage'
p4041
aS'adults 30'
p4042
aS'fever chills'
p4043
aS'co purified'
p4044
aS'8 general'
p4045
aS'statistically significant'
p4046
aS'gene vaccine'
p4047
aS'carrier'
p4048
aS'candidate and 10'
p4049
aS'cytokine'
p4050
aS'time day'
p4051
aS'term consequences'
p4052
aS'Also chronic'
p4053
aS'neither irritating nor'
p4054
aS'HBcAg over'
p4055
aS'compromised hosts'
p4056
aS'Sera'
p4057
aS'Two'
p4058
aS'12h post'
p4059
aS'spontaneously and patients'
p4060
aS'nasal conditions occurred'
p4061
aS'device Also chronic'
p4062
aS'test for continuous'
p4063
aS'specialized'
p4064
aS'liquid Each vial'
p4065
aS'Control CECMED'
p4066
aS'immunosorbent assay anti'
p4067
aS'exposure to hepatitis'
p4068
aS'X02763'
p4069
aS'nasally parenteral'
p4070
aS'individuals renal'
p4071
aS'group and one'
p4072
aS'careful performance'
p4073
aS'first vaccine dose'
p4074
aS'Biotechnology Havana Cuba'
p4075
aS'inflammatory Th1'
p4076
aS'exposure'
p4077
aS'recruited'
p4078
aS'71 in recipients'
p4079
aS'transparent liquid Each'
p4080
aS'first hour after'
p4081
aS'range 18'
p4082
aS'interest'
p4083
aS'first dose injection'
p4084
aS'immunogenicity in populations'
p4085
aS'volunteer generating'
p4086
aS'attributed'
p4087
aS'formal hypothesis testing'
p4088
aS'HBV infected patient'
p4089
aS'immunity elicited'
p4090
aS'over nasally'
p4091
aS'Following'
p4092
aS'prevent permanent impairment'
p4093
aS'responses against HBsAg'
p4094
aS'conditions occurred during'
p4095
aS'were fatal'
p4096
aS'administered through'
p4097
aS'recipients according'
p4098
aS'evident'
p4099
aS'immune compromised'
p4100
aS'Ethics Board'
p4101
aS'among individuals'
p4102
aS'signed'
p4103
aS'protein nature'
p4104
aS'wash and saliva'
p4105
aS'carriage'
p4106
aS'sterile saline solution'
p4107
aS'reporting specific post'
p4108
aS'treatment with blood'
p4109
aS'distribution'
p4110
aS'associated with functional'
p4111
aS'formulated with 50'
p4112
aS'display'
p4113
aS'4 9 Only'
p4114
aS'block'
p4115
aS'reported to elicit'
p4116
aS'rabbits'
p4117
aS'showing induction'
p4118
aS'measure'
p4119
aS'generating'
p4120
aS'Thirty days after'
p4121
aS'dose and sera'
p4122
aS'treatment group sample'
p4123
aS'were randomized'
p4124
aS'used as placebo'
p4125
aS'hematological'
p4126
aS'nasal vaccines currently'
p4127
aS'achieved antibody levels'
p4128
aS'CIGB production'
p4129
aS'attention Serious adverse'
p4130
aS'Briefly anti HBs'
p4131
aS'detect differences between'
p4132
aS'l seroprotection'
p4133
aS'43'
p4134
aS'volunteers without'
p4135
aS'anti HBs only'
p4136
aS'subjects showing antibody'
p4137
aS'Five'
p4138
aS'helpful'
p4139
aS'normal'
p4140
aS'individuals renal dialysis'
p4141
aS'30 one'
p4142
aS'6 13 excess'
p4143
aS'formulation Phase'
p4144
aS'15 minutes'
p4145
aS'body system'
p4146
aS'field of devices'
p4147
aS'had not achieved'
p4148
aS'infection Conversely'
p4149
aS'7 days post'
p4150
aS'primary outcome'
p4151
aS'screen failures included'
p4152
aS'recognize any local'
p4153
aS'adverse effects predominated'
p4154
aS'factors'
p4155
aS'persistent'
p4156
aS'minutes apart'
p4157
aS'B surface'
p4158
aS'HBs antibody were'
p4159
aS'analysis There'
p4160
aS'volumes'
p4161
aS'one subject'
p4162
aS'nasal immunogenicity'
p4163
aS'each rate percentages'
p4164
aS'infection or immunization'
p4165
aS'T cell immune'
p4166
aS'cell immune'
p4167
aS'responsiveness'
p4168
aS'major HBV antigens'
p4169
as.